ANNUAL REPORT

2022
Volume 4

CONTENTS
Preface––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 3
Organization–––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 4
Division of Science–––––––––––––––––––––––––––––––––––––––––––––––––– 5
Division of Education–––––––––––––––––––––––––––––––––––––––––––––––– 7
Division of Safety Management–––––––––––––––––––––––––––––––––––––––– 9RadioIsotope Research Center––––––––––––––––––––––––––––––––––––––––– 11I

Research Activity
Genome analysis of radiosensitive and cancer-prone Medaka rev3l mutants:
Unraveling the mechanisms of high cancer susceptibility

15

ISHIKAWA-FUJIWARA, T.; TODO, T.

Investigation of novel drug for alpha-emitting nuclear medicine targeting tocancer specific amino acid transporter, LAT1
KANEDA-NAKASHIMA, K.; MANABE, Y.; SHIMOYAMA, A.; KABAYAMA, K.; WATABE, T.; KANAI, Y.;
OOE, K.; TOYOSHIMA, A.; SHIRAKAMI, Y.; YOSHIMURA, T.; FUKUDA, M.; NAKANO, T.; FUKASE, K.

Development of rare-gas matrix-isolation apparatus for γ-ray measurment of 229mTh
MASUDA, R.; YASUDA, Y.; SAWAMURA, K.; SHIGEKAWA, Y.; MIYAMOTO, Y.; YOSHIMURA, K.; SHINOHARA, A.; KASAMATSU, Y.

Stability Evaluation of a Series of the Lanthanide Complexes with
Tripod-type Nonadentate Ligand Having Picolinic Acid Arms

16

17
18

NAGATA,K .; ISHIDA, Y.; YAJIMA T.; YOSHIMURA, T.

Physiological, genomic effects in descendant mice after the every generational
low dose-rate internal 137Cs radiation exposure

19

NAKAJIMA, H.; OHNO, M.; TOKI, H.

Non-destructive Determination of Bulk elemental composition forasteroid Ryugu by muon elemental analysis method

20

NINOMIYA, K.; CHIU, I-H. and Muon elemental analysis team.

Oxidation of Cu-Au Alloy Surface by Oxygen Molecular Beam
OKADA, M.

Investigation of chemical purification method for Ce-141 as candidate nuclide for radiotheranostics
OOE, K.; WATABE, T.; SHIRAKAMI, Y.; NAMBU, A.; HABA, H.; HATAZAWA, J.

Synthesis and preclinical evaluation of PSMA derivatives labeled with astatine-211
SHIRAKAMI, Y.; KANEDA-NAKASHIMA, K.; WATABE, T.; KADONAGA Y.; OOE, K.; KON, Y.; HABA, H.; YIN, X.;
TOYOSHIMA, A.; FUKASE, K.

Project to collect accidents and incidents for the creation of educational and training materials
SUZUKI, T.; HIGAKI, S.; TAKAHASHI, M.

21
22
23
24

Direct Detection of Gamma-Rays from Laser Plasma
TAMII, A.; IWASAKI, R.; KOBAYASHI, N.; INOUE, A.; NIINA, R.; OTA, S.; SUDO, T.; ROKUJO, H.;
NAKAZAWA, K.; NISHIUCHI, M.; SAKAKI, H.; KONDO, K.; KON, A.; LIU, C.; KAWABATA, T.; FURUNO, T.;
TSUJI, S.; MIYAMOTO, K.; HONDA, Y.; NIIKURA, M.; WIELAND, O.

Revealing ultrafast vibronic dynamics of tetracene moleculeswith sub-8 fs UV impulsive Raman spectroscopy
TERAMOTO, T.; LIU, J.; DU, J.; KOBAYASHI, T.

Targeted α-therapy using astatine(211At)-labeled PSMA: a preclinicalevaluation as a novel compound
WATABE, T.; KANEDA-NAKASHIMA, K.; SHIRAKAMI, Y.; KADONAGA, Y.; OOE, K.; TOYOSHIMA, A.; GIESEL, F. L.;
TOMIYAMA, N.; FUKASE, K.

Enrichment of 48Ca by Laser Isotope Separation for the Study of Double Beta Decay
RITTIRONG, A.; YOSHIDA, S.; UMEHARA, S.; OGAWA, I.; TOKITA, S.

Synthesis of Octahedral Hexanuclear Rhenium Complexes as a Molecular Targeted AgentNISHIZAWA, H.; NAGATA, K.; KANEDA-NAKASHIMA, K.; YOSHIMURA, T.

1

IRS ANNUAL REPORT

2022

25

26

27
28
29

II

Achievements
Original Papers––––––––––––––––––––––––––––––––––––––––––––––––––––––– 31
Biblios––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 37
Presentations––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 38
Awards––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 45
Social and Academic Contributions–––––––––––––––––––––––––––––––––––––– 45
Patents––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 46
Fund for Preparation of New Education and Research Projects––––––––––––– 47
Division Summary––––––––––––––––––––––––––––––––––––––––––––––––––––– 52
Division of Science–––––––––––––––––––––––––––––––––––––––––––––––––– 53
Division of Education–––––––––––––––––––––––––––––––––––––––––––––––– 55
Division of Safety Management–––––––––––––––––––––––––––––––––––––––– 57
Radioisotope Research Center––––––––––––––––––––––––––––––––––––––––– 58

Name Index––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 59

IRS ANNUAL REPORT

2022

Volume 4

IRS ANNUAL REPORT

2022

2

Preface
It is our pleasure to present the Annual Report 2022 of the Institute for Radiation
Sciences (IRS), Osaka University.
The IRS was established in 2018 in Osaka University, and it brings together all theradiation facilities at Osaka University to optimize their resources and advantages indeveloping and realizing advancements in radiation science.
The missions of the IRS are to reinforce education, research, and safety management
relating to radiation sciences, to solve global issues for the future, and to develop humanresources by pioneering novel research fields. The IRS is a unique department utilizing
the open-minded advantages of Osaka University by consolidating all of the radiation
facilities at the university.
The IRS is developing the Targeted Alpha Therapy in collaboration with fundamental
science groups (the Graduate School of Science, etc.), an accelerator facility (the ResearchCenter for Nuclear Physics), groups of nuclear medicine, tracer kinetics, diagnostic
and interventional radiology (the Graduate School of Medicine), and Osaka University
Hospital, under the research and development project, “Promotion of nuclear-medicine
innovation by the establishment of Institute for Radiation Sciences” (FYs 2018-2022). At
the same time, we are improving radiation safety education for students including thosefrom countries in Southeast Asia and are building new cross-disciplinary research and aradiation safety management education program for the whole university.
This annual report summarizes our scientific achievements in 2022. I sincerely hope thatthese achievements will inspire further advances, promote worldwide collaborations with
our scientists in the IRS, and ultimately, produce invaluable outcomes and values that can
only be attributed to the unified efforts of the radiation facilities of Osaka University.
October 2023

TOMIYAMA, Noriyuki, M.D., Ph.D.
Director
Institute for Radiation Sciences
Osaka University

3

IRS ANNUAL REPORT

2022

Organization

Steering
Committee
Division of Science

Director

DeputyDirector

Institute
Committee

Division of Education

Division of
Safty Management

Radiation Facility of
Each Department*1, *2

Management Ofﬁce ofEach Radiation Facility

Radioisotope
Research Center*1 Radiation-related facilities(1) Radio Isotope Experiment Laboratory,
		 Graduate School of Science * Note1(2) Radiation Science Experiment Laboratory,
		 Graduate School of Science * Note1(3) Radioisotope Usage Facility,
		 Graduate School of Medicine * Note2(4) Radioisotope Usage Facility, Division of Health Science,
Graduate School of Medicine(5) Radioisotope Medical Care Facility,
		 Osaka University Hospital(6) Radioisotope Medical Care Facility,
		 Osaka University Dental Hospital(7) Radioisotope Usage Facility,
		 Graduate School of Engineering(8) Radiation Generator Usage Facility,
		 Institute of Free Electron Laser,		 Graduate School of Engineering(9) Radioisotope Usage Facility,
		 Graduate School of Frontier Biosci­ences(10) Radio Isotope Experiment Laboratory,
		 Research Institute for Microbial Diseases(11) Radioisotope Usage Facility,
		 The Institute of Scientific and Industrial Research(12) Radioisotope Usage Facility,
		 Institute for Protein Research(13) Radioisotope Usage Facility,
		 Institute of Laser Engineering Usage Facility of		 Ultra-high Voltage Electron Microscope Selective(14) Radiation Generator(15) Radioisotope Usage Facility,
		 Radioisotope Research Center (Suita branch)(16) Radioisotope Usage Facility,
		 Radioisotope Research Center (Toyonaka branch)(17) Radioisotope Usage Facility,
		 Nuclear Physics Research Center*2 Nuclear Fuel Usage Facility(1) Department of		 Sustainable Energy and Environmental Engineering,
		 School of Engineering(2) Radiation Science Experiment Laboratory,
		 Graduate School of Science

Note1 : Integrated with RI Radioisotope Research Center (Toyonaka branch) from April 1, 2018
Note2 : Integrated with RI Radioisotope Research Center Suita from April 1, 2021

IRS ANNUAL REPORT

2022

4

Division of Science

Members and 49 concurrent post members
Professor

Professor

Spec. App. Assoc. Prof.

Spec. App. Assoc. Prof.

FUKASE, Koichi

SHIRAKAMI, Yoshifumi

TOYOSHIMA, Atsushi

Specially Appointed Prof.

YONEKURA, Yoshiharu

TERAMOTO, Takahiro

Goals and Objectives 2022
Targeted alpha-particle therapy has been investigated for the development of new therapies
for refractory cancer through collaboration with the Graduate School of Science, Graduate
School of Medicine, and Research Center for Nuclear Physics. The joint research with the
Graduate School of Dentistry was newly initiated. In April 2022, a joint research laboratory,“Astatine Drug Discovery and Practical Application Joint Research Division” was establishedin partnership with Alpha Fusion Co., Ltd. Comprehensive studies including clinical trials,
non-clinical studies, and development researches were conducted with the support of Alpha
Fusion’s human resources and funding.

Achievements 2022
1. Physician-initiated clinical trial of [211At]NaAt for refractory thyroid cancer
A Phase I investigator-initiated clinical trial using [ 211 At]NaAt was conducted incollaboration with the School of Medicine and the Osaka University Hospital.
2. Non-clinical studies of 211At-PSMA in prostate cancer
Lead optimization studies were conducted on prostate cancer drugs targeting prostatespecific membrane antigen (PSMA) to select a candidate compound for the non-clinicalstudies, which were initiated in collaboration with the School of Medicine and the Osaka
University Hospital. A PCT application was filed: PCT/JP2022-29283, application date: July29, 2022.
3. Studies on 211At-FAPI
A series of 211At-FAPI compounds targeting fibroblast activating protein (FAP) in cancer
stroma were synthesized and their anti-tumor effects were evaluated. Further optimizationis still needed. A PCT application was filed: PCT/JP2023-00610, application date: February
21, 2023.
5

IRS ANNUAL REPORT2022

https://www.irs.osaka-u.ac.jp/department/science_mission.html

4. Studies on 211At-gold nanoparticles
Cancer treatments with 211At-gold nanoparticles by direct tumor administration, tail vein
administration, or intraperitoneal administration were investigated. Local administration
to C6 glioma-implanted rats and PANC1-implanted mice showed marked tumor growth
inhibition. A novel study on tongue cancer was initiated with the School of Dentistry.
5. Studies targeting L-type amino acid transporter (LAT1)
LAT1 is an amino acid transporter that exhibits selective expression in diverse tumor types.
Research endeavors have focused on the development of LAT1 substrates with enhanced
accumulation and retention characteristics compared to 211At-AAMT. In an animal modelutilizing cells derived from a drug-resistant strain of pancreatic cancer (gemcitabineresistant), the 211At-L-α-methyl-O-methyl-tyrosine (L-211At-AAMT-OMe) demonstrated
remarkable therapeutic efficacy. Other backup compounds were also developed. Patent
Application 2022-150608, application Date: September 22, 2022.
6. New 211At labeling methods using anodic oxidation or photo-irradiation
7. Studies on 211At-labeled antibodies
PCT/JP2022/035783
8. Research on various novel modalities
Several new drug candidates of novel modalities (mid-sized molecules, peptides) withexcellent tumor delivery and cell internalization capabilities were investigated.
9. Novel beta-ray therapeutic nuclide 47Sc
The novel beta-ray therapeutics using 47Sc have been investigated by the collaboration with
Research Center for ELectron PHoton Science (ELPH), Tohoku University.
10.Others
Production and supply of 211At using the AVF cyclotron at the Research Center for Nuclear
Physics were re-started.

Selected Publications 2022
1) Watabe T, Liu Y, Kaneda-Nakashima K, Sato T, Shirakami Y, Ooe K, Toyoshima A, Shimosegawa E, Wang Y, Haba H, Nakano T, Shinohara A, Hatazawa J.
Comparison of the Therapeutic Effects of [211At] NaAt and [131I] NaI in an NIS-Expressing Thyroid Cancer Mouse Model. Int. J. Mol. Sci. 2022, 23(16), 9434; https://doi.org/10.3390/ijms23169434
2) Kaneda-Nakashima K, Shirakami Y, Watabe T, Ooe K, Yoshimura T, Toyoshima A, Wang Y, Haba H, Fukase K. Effect to Therapy of Sodium-Iodine Symporter
Expression by Alpha-Ray Therapeutic Agent via Sodium/Iodine Symporter. Int. J. Mol. Sci. 2022, 23(24), 15509; https://doi.org/10.3390/ijms232415509
3) Yonekura Y, Toki H, Watabe T, Kaneda-Nakashima K, Shirakami Y, Ooe K, Toyoshima A, Nakajima H, Tomiyama N, Bando M. Mathematical Model for Evaluationof Tumor Response in Targeted Radionuclide Therapy with 211At Using Implanted Mouse Tumor. Int J Mol Sci. 2022 Dec 15;23(24):15966.
4) Hertz B, Watabe T, Baum RP. Celebrating 80 years anniversary of radioiodine for use in thyroid cancer and perspectives for theranostics. Ann Nucl Med. 2022
Dec;36(12):1007-1009.
5) Suzuki K, Iwai H, Utsunomiya K, Kono Y, Watabe T, Kobayashi Y, Bui DV, Sawada S, Yun Y, Mitani A, Fukui K, Sakai H, Chu HH, Linh NM, Tanigawa N, Kanda A.
Efficacy of Combination Therapy with Lenvatinib and Radioactive Iodine in Thyroid Cancer Preclinical Model. Int J Mol Sci. 2022 Aug 30;23(17):9872.
6) Watabe T, Kaneda-Nakashima K, Shirakami Y, Kadonaga Y, Ooe K, Wang Y, Haba H, Toyoshima A, Cardinale J, Giesel FL, Tomiyama N, Fukase K. Targeted
α-therapy using astatine (211At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound. Eur J Nucl Med Mol Imaging. 2022 Nov 8. doi: 10.1007/
s00259-022-06016-z.
7) Kaneda-Nakashima K, Shirakami Y, Kadonaga Y, Watabe T. Fibroblast activation protein inhibitor theranostics: Pleclinical Considerations. PET Clinics 2023,
https://doi.org/10.1016/j.cpet.2023/02/005
8) Aso A, Kaneda-Nakashima K, Nabetani H, Kadonaga Y, Shirakami Y, Watabe T, Yoshiya T, Mochizuki M, Koshino Y, Ooe K, Kawakami A, Jinno N, Toyoshima A,
Haba H, Wang Y, Cardinale J, Giesel FL, Shimoyama A, Fukase K. Substrate Study for Dihydroxyboryl Astatine Substitution Reaction with Fibroblast Activation
Protein Inhibitor (FAPI). Chem Lett. 2022; 51(11): 1091-1094. https://doi.org/10.1246/cl.220391
9) Huang X, Kaneda-Nakashima K, Kadonaga Y, Kabayama K, Shimoyama A, Ooe K, Kato H, Toyoshima A, Shinohara A, Haba H, Wang Y, Fukase K. Astatine211-Labeled Gold Nanoparticles for Targeted Alpha-Particle Therapy via Intravenous Injection. Pharmaceutics 2022, 14(12), 2705; https://doi.org/10.3390/
pharmaceutics14122705

IRS ANNUAL REPORT

2022

6

Division of Education

Members and 23 concurrent post members
Professor

OKADA, Michio

Specially Appointed Prof.

NOMACHI, Masaharu

Associate Professor

NAKAJIMA, Hiroo

Specially Appointed Researcher

ISHIKAWA-FUJIWARA, Tomoko

Goals and Objectives 2022
Division of Education promotes the education of radiation sciences across the University.
Combining campus wide activities on human resource development, various radiationeducation programs can be proceeded more efficiently and effectively. We also intend toconstruct high-level radiation education programs and the related international programs.

Achievements 2022
Osaka University set up “Graduate Programs for Advanced Interdisciplinary Studies” that
could provide motivated students with an opportunity to master the basics in a wide range offields while focusing on an advanced. “Radiation science” has been implemented as a programby our Institute from this fiscal year with the cooperation of Research Center for Nuclear
Physics, Graduate School of Science, and Graduate School of Medicine. In the future, withthe cooperation of even more departments, we plan to expand the educational program intoa cross-disciplinary program. We rename the program as “Co-creative Radiation Education
Programme (CREPE)”, where some courses are newly offered by the Graduate School ofEngineering. CREPE for graduate students has been adopted for the 2023 academic year.
We carried out the Nuclear Regulatory Human Resources Development Project in this fiscal
year, the project title of “Nuclear Regulatory Human Resources Development Program by
Co-creation with Society”. This project is the 5-years project where the radiation-education
program for the undergraduate students, organized around the FUKUSHIMA Environmental
Radiation Workshop, is expected to be developed. Continuing from the previous year, the7

IRS ANNUAL REPORT2022

https://www.irs.osaka-u.ac.jp/department/education_mission/“Co-creative Radiation Education Programme (CREPE)” was held. In the fiscal year 2022,
30 students were registered for the course, and 7 of them completed the program in March
2023. We have revised a homepage (https://www.rcnp.osaka-u.ac.jp/crepe/) and a pamphlet to
publicize this CREPE program. CREPE students held a poster exhibition at Osaka University
Co-creation DAY@EXPOCITY on June 11. At this event, CREPE students introduced theiractivities in Fukushima to the general public. In addition, we participated in the Fukushima
Prefecture Hamadohri District Environmental Radiation Workshop, which is the main subjectof CREPE, as a radiation education division. On Saturday, July, a pre-lecture will be held for
3 days ahead of the on-site training of environmental radiation, and from August 21st to 26th
(5 nights and 6 days) and September 18th to 23rd, the training of environmental radiation
was held in the Hamadohri district of Fukushima prefecture. The number of participating
students increased to 123, including those from other universities. The results of this workshop
were presented by the students at the final discussion of the workshop held on August 29th
and September 26th at Toyonaka Campus, Osaka University. At the workshop held in August,Director Tanaka, who was in charge of education, visited the facility and received a highevaluation.
Division of Radiation Education provided “Natural Sciences, Sociology, and Humanities
Related to Radiation” as a basic liberal arts subject of general education in Osaka University.
This subject is open to all faculties and grades and offers cross-disciplinary study of radiationrelated physics, chemistry, biology, medicine, law, economics, and social psychology. The scienceand humanities students were educated so that they could understand radiation from various
angles and become facilitators for risk communication. There were 20 students registered, and14 passed. This time, there were students who were able to take courses for graduate students.
In 2022, we invited a lecturer from the Nuclear Regulation Authority to give a lecture, which
was very well received by the students.
The door to learning (Gakumon heno Tobira) “Science of radiation around us” wasimplemented as a mechanism. The number of registered students was 17. One graduate student
conducted TA for this program.
In FY2022, JST Sakura Science Program September was held in conjunction with theHamadori District Environmental Radiation Workshop in Fukushima Prefecture.
In February, an international symposium was held at the University of Groningen bysending two undergraduate students studying CREPE. (https://www.osaka-u.ac.jp/ja/news/
topics/2023/04/03001)

IRS ANNUAL REPORT

2022

8

Division of Safety Management

Members and 24 concurrent post members
Professor

YOSHIMURA, Takashi

Assistant Professor

SUZUKI, Tomokazu

Technical Staff

KON, Yukiyoshi

Technical Staff

KOKI, Ryoichi

Division of safety management works together with radiation facilities and nuclear fuel facilities
with respect to radiation safety management and sums up radiation safety management in our
university. Radioisotope research center undertakes a role of the center of the division andliaises closely with staffs of the facilities. The risk management system is constructed that thestaffs of the institute cooperate and support to settle an emergency and accident and to provide
information of the situation.

9

IRS ANNUAL REPORT2022

https://www.irs.osaka-u.ac.jp/department/management.html

Achievements 2022
1) Assistance to obtain the license of Radiation Protection Supervisor
In order to encourage to obtain the license of Radiation Protection Supervisor, we aided
tuition and travel expenses for obtaining the license to two persons who plan to become thesupervisor or its deputy supervisor in the radiation facilities in the university.
2) Cooperation in safety and management inspection activities forradiation facilities on the campuses
In this year, a self-inspection in each radiation facility and inspection from the members of
this division and radioisotope research center (the inspection committee members) wereconducted. After each facility conducted its self-inspection, a meeting was held in October(the first meeting) with inspection committee members. At the meeting, details of inspection
were confirmed. The inspection committee members visited each facility and conducted
inspections from November to December. A second meeting was held in February to share
the results of the inspections at each facility. The reports of these inspections were compiled
into a booklet and distributed to the university headquarters, related departments, andrelated parties.

IRS ANNUAL REPORT

2022

10

RadioIsotope Research Center
Members and 16 concurrent post members
Director

Co-Director

Professor

Associate Professor

Associate Professor

Assistant Professor

MURATA, Isao

NINOMIYA, Kazuhiro

KAWABATA, Takahiro

OOE, Kazuhiro

YOSHIMURA, Takashi

NAGATA, Kojiro

Radioisotope Research Center (RI center) has buildings in Suita and Toyonaka campuses. RI
center Suita is a main building, and this building is a core facility of Institute for Radiation
Sciences. RI center Toyonaka is a branch. In RI center Suita, the research of alpha-particle
nuclear therapy project has conducted. 211At produced in RIKEN and QST Takasaki transported
to RI center Suita, and then separation from an irradiated target material, purification of 211At,
syntheses of labelled compounds, and animal experiments were performed in the center. The
purpose of RI center is to provide education and training of radiation safety to radiation workers
in the university, to maintain and provide the facilities and experimental equipment in Suita andToyonaka Campuses to the radiation workers, and to conduct radiation safety management andrelated research.

11

IRS ANNUAL REPORT2022

https://www.irs.osaka-u.ac.jp/department/ri_mission.html

Achievements 2022
1) Radiation safety management, and education and training for radiation workers
Environment measurements in the radiation facilities were carried out for 179 working
rooms of 13 facilities on Suita and Toyonaka campuses. We managed and operated thesystem for management of radiation workers (the number of registered users: 3,444). Fifteentimes of education and training to radiation workers (total participants: 1,921) were heldusing the CLE system, Osaka University.
2) Radiation education
As the safety education, we encouraged students to take the Radiation Protection Supervisor
Examination and conducted the online preparatory lecture using CLE (participants: 32).
Application forms for the examination were distributed.
3) Use of radiation facilities in RI center
The number of applications for joint use of RI center facilities was 53, and the number ofusers were 616.

Selected Publications 2022
1) K. Baba, K. Nagata, T. Yajima, T. Yoshimura, Synthesis, Structures, and Equilibrium
Reactions of La(III) and Ba(II) Complexes Pyridine Phosphonate Pendant Arms on a Diaza18-crown-6 Ether, Bull. Chem. Soc. Jpn. 95, 466-475 (2022).

IRS ANNUAL REPORT

2022

12

13

IRS ANNUAL REPORT

2022

Research Activity

I

IRS ANNUAL REPORT

2022

14

Genome analysis of radiosensitive andcancer-prone Medaka rev3l mutants:
Unraveling the mechanisms ofhigh cancer susceptibility
ISHIKAWA-FUJIWARA, Tomoko* and TODO, Takeshi
Radioisotope Research Center, Institute for Radiation Sciences, Osaka University* fujiwara.tomoko.irs@osaka-u.ac.jp

I
Research Activity

Genome homeostasis is fundamental to life, and all organisms have strict genome maintenancemechanisms. Genome maintenance is an extremely complex system involving many factors andpathways. The phenotype caused by disruption of each factor provides valuable information
for understanding the overall picture of complex mechanism. In order to establish a model
system for analyzing the genome maintenance mechanism, we have comprehensively generated
mutants of genes involved in genome maintenance in medaka fish. As a result, we obtained avery unique mutant that spontaneously develops intestinal tumor in all individuals in an agedependent manner under normal breeding conditions. In the culture cell established fromthis mutant we have detected multiple double-strand breaks (DSBs), and also found frequent
induction of chromosomal aberrations. In addition, we have detected genomic structuralvariants in cancer cells at an extremely high level. DSB is a representative radiation damage
and one of the main factors of radiation carcinogenesis. This mutant not only provides an
excellent in vivo system for mechanism analysis from DSB to carcinogenesis, but is also
considered to be a suitable model system for analyzing the biological effects of radiation. We
are planning to conduct histological analysis of carcinogenic individuals at their early stages.
To search for molecular markers for the histological analysis, this year we performed gene
expression analysis of cancer tissues by RNA-seq. This intestinal cancer is characterized
by infiltration of cancer cells into surrounding tissues such as the liver and ovaries anddissemination into the peritoneal cavity in almost all carcinogenic individuals. Epithelialmesenchymal transition (EMT) plays an important role in cancer cell invasion and metastasis.
As a result of RNA-seq, most of the retrieved EMT-related genes were found to be abnormally
expressed in tumor-bearing intestinal tissue. Human colorectal cancer is classified into fourmolecular subtypes (CMS1-4) according to gene expression patterns. Among them, CMS4 ischaracterized by frequent invasion and metastasis, and abnormal expression of EMT-related
genes was observed in this subtype. Our results indicate that this mutant has a phenotype
very similar to the CMS4 subtype of human colorectal cancer. We would like to proceed withhistological analysis using EMT-related gene expression abnormalities as indicators.

15

IRS ANNUAL REPORT

2022

Investigation of novel drug foralpha-emitting nuclear medicine targeting tocancer specific amino acid transporter, LAT1
KANEDA-NAKASHIMA, Kazuko;1,2 MANABE, Yoshiyuki;1,2,3 SHIMOYAMA, Atsushi ;1,2,3
KABAYAMA, Kazuya;1,2,3 WATABE, Tadashi;1,2,5 KANAI, Yoshikatsu;1,2,6OOE, Kazuhiro;1,2,5
TOYOSHIMA, Atsushi;1,2 SHIRAKAMI, Yoshifumi;1,2,5 YOSHIMURA, Takashi;1,2,7
FUKUDA, Mitsuhiro;1,2,8 NAKANO, Takashi2,8 and FUKASE, Koichi1,2,3
1 MS-CORE, FRC, Graduate School of Science, Osaka University
2
Division of Science, Institute for Radiation Sciences, Osaka University
3
Laboratory for Natural Product Chemistry, Graduate School of Science, Osaka University
4
Laboratory for Radiochemistry, Graduate School of Science, Osaka University
5
Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University
6
Department of Bio-System Pharmacology, Graduate School of Medicine, Osaka University
7
Radioisotope Research Center, Institute for Radiation Sciences, Osaka University
8
Research Center for Nuclear Physics, Osaka University

I
Research Activity

kanedak17@chem.sci.osaka-u.ac.jp

Targeted alpha therapy (TAT) is receiving much attention in the field of “Theranostics” becauseof its high cytotoxic effect to the targeting cancer. However, physiological uptakes in nontargeted organs are also observed in the TAT, which might lead to the severe side effects. We
should consider about both maximizing the treatment effect in the tumor and minimizing
the side effects in the organs at risk. From this viewpoint, decision of targeting molecule
was most important. We selected LAT1 as molecular target. LAT1 is one of the amino acidtransporters, which has highly specificity to cancer tissues. We developed next-generationinternal radiotherapy using chemicals targeting LAT1. First, we synthesized alpha-methyl-Ltylosine labeled with 211At. 211At was produced by the cyclotron, and then quickly purified andlabeled (211At-AAMT). Next, we performed its cytotoxicity evaluation using some cancer celllines. As a result, cell death and specificity were confirmed. We also confirmed the specificity invivo. We examined that the effects of 211At-AAMT using several kinds of tumor-bearing models.
Furthermore, we established the labeling technique without using mercury. From these facts,
211
At-AAMT has the potential to be a safe and versatile drug for several cancers.
In this year’s study, we were able to confirm its efficacy in the models with lung cancer andosteosarcoma cell lines. Thus, we applied for one patent this year (Japanese Patent Application
No. 2022-150608). It also obtained four private grants and one grant from Advanced Researchand Development Programs for Medical Innovation (AMED). We developed the structure ofa better compound and proceeded with preliminary studies for non-clinical trials. In the nextyear, we plan to prepare for non-clinical studies, including consulting with Pharmaceuticals
and Medical Devices Agency (PMDA).

Reference[1] KANEDA-NAKASHIMA, K.; SHIAKAMI, Y.; WATABE, T.; OOE, K.; YOSHIMURA, T.; TOYOSHIMA, A.; WANG,
Y.; HABA, H.; FUKASE, K. International Journal of Molecular Sciences, 2022, 23(24), 15509

IRS ANNUAL REPORT

2022

16

Development of
rare-gas matrix-isolation apparatus for
γ-ray measurment of 229mTh
MASUDA, Ryoutarou;1,2 YASUDA, Yuki;1 SAWAMURA, Kei;1 SHIGEKAWA, Yudai;3
MIYAMOTO, Yuki;4 YOSHIMURA, Koji;4 SHINOHARA, Atsushi2,5 and KASAMATSU, Yoshitaka1,2,3
1 Graduate School of Science, Osaka University
2 Institute for Radiation Sciences, Osaka University
3 RIKEN Nishina Center for Accelerator-Based Science
4 Research Institute for Interdisciplinary Science, Okayama University
5 Osaka Aoyama University

I

masudar21@chem.sci.osaka-u.ac.jp

Research Activity

The first excited state in the 229Th nucleus, 229mTh, has an extremely low excitation energy of
8.30±0.92 eV, which is 3-6 orders of magnitude smaller than those of other isomers. Therefore,
the decay path of 229mTh is reported to change depending on its chemical state. We havedeveloped a new rare-gas matrix isolation apparatus to directly observe γ rays from 229mTh,
which leads to the determination of the accurate excitation energy and in the observation of thechanges of the nuclear decay depending on the chemical state.
To observe γ ray from 229mTh, it is required to stably maintain its chemical state in which 229mTh
is expected to emit the γ ray, and to detect the vacuum ultraviolet (VUV) photons from a 229mTh
sample. By the rare-gas matrix isolation method, 229mTh is surrounded by rare gases which
are inert atoms and intermolecular interactions are negligible. If the high valence 229mTh ionsrecoiled from 233U by α decay are trapped in the rare gas solid, the implanted 229mTh ions would
be isolated.
We developed the rare-gas matrix isolation apparatus in which the detection efficiency for VUVphotons is ~7.4 %. The half-life of 229mTh for the γ transition is estimated to be 5000 s. The γ
ray emission counting rate from 229mTh is expected to be 100-2000 counts per second (cps) byusing a 10000 Bq 233U source. We used Ar (99.99994 % purity) gas for producing noble gas
solids. The substrate was cooled to about 10 K by a Gifford-McMahon refrigerator, and the
Ar gas was blown onto the substrate. The flow rate of the Ar gas was adjusted by a mass flow
controller to 30 cc/min. The stable and low noise photon detection conditions for a long time
were determined for the observation of photons from 229mTh. In the background measurements,
stable photon counting rate for longer than 24 h was implemented. The average count rate
was 0.28 cps, which is well below the estimated count rate for 229mTh photons. We measured
Cherenkov photons from 137Cs and 228Th sources and thereby estimated that the Cherenkov
backgrounds from the 233U source are negligibly small. Under these conditions, we plan toobserve 229mTh γ ray.

17

IRS ANNUAL REPORT

2022

Stability Evaluation of a Series of
the Lanthanide Complexes with Tripod-type
Nonadentate Ligand Having Picolinic Acid Arms
NAGATA, Kojiro;*1 ISHIDA, Yohta;2 YAJIMA Tatsuo3 and YOSHIMURA, Takashi2
1 Radioisotope Research Center, Institute for Radiation Sciences, Osaka University
2 Department of Chemistry, Graduate School of Science, Osaka University
3 Department of Chemistry and Materials Engineering, Faculty of Chemistry, Materials and Bioengineering, Kansai University* knagata@chem.sci.osaka-u.ac.jp

I

153

Research Activity

Sm, 161Tb, and 177Lu are candidate nuclides with half-lives of several hours to several days andemit low-energy beta particles, which have potential applications in nuclear medicine therapy.
In order to apply these nuclides in medicine, it is necessary to form thermodynamically andkinetically stable metal complexes. Therefore, we have synthesized a new tripod-type ligand
H3L with picolinate moiety. Since hydrated complexes of lanthanide(Ln) ions form a ninecoordinated tri-capped trigonal prismatic (TPP) geometry, we designed this ligand to form thesimilar coordination geometry. In this study, a series of lanthanide complexes were synthesized
by using H 3L, and the thermodynamic stability and acid decomposition reactions of theobtained complexes were evaluated.
The Ln complexes were isolated by reacting each Ln triflate [Ln = La, Ce, Pr, Nd, Sm, Eu,
Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, (Y)] with H3L at room temperature in water. The 1H NMR
signals of La, Y, and Lu complexes without unpaired electrons in the obtained complexes wereobserved to have C3 symmetry, but all of them changed to more complicated C3 symmetricsignal than H3L. In addition, elemental analysis revealed that all of these complexes form a 1:1
complex between the ligand and the Ln3+ ion. From the results of single crystal X-ray analysis,
it was found that all of the Ce~Lu complexes, except for the La complex, have the ninecoordinated TPP geometry. As the ionic radius of the lanthanides decreased from La to Ln, thebonding distances of each M-N and M-O gradually shortened. The results of potentiometrictitration showed that the log KML values of the thermodynamic stability constants of thesecomplexes ranged from 12 to 16. These values are comparable to those of the previously
reported complexes with picolinic acid moieties.
Finally, the rate constant k obs for the acid decomposition reaction in perchloric acid was
unexpectedly found to be minimal for the HoL complex. In other words, from LaL to HoL, kobs
tended to decrease with decreasing ionic radius, while from HoL to LuL, kobs conversely tended
to increase. This may be due to the fact that protonation of the secondary amine moiety is more
likely to occur for Ln ions with smaller ionic radii than Ho3+.

IRS ANNUAL REPORT

2022

18

Physiological, genomic effects in descendantmice after the every generational low dose-rateinternal 137Cs radiation exposure
NAKAJIMA, Hiroo;1* OHNO, Mizuki2 and TOKI, Hiroshi3
1 Institute for Radiation Sciences, Osaka University
2 Dept. of Medical Biophysics and Radiation Biology, Faculty of Med. Sci., Kyushu University
3 Research Center for Nuclear Physics, Osaka University* nakajima@irs.osaka-u.ac.jp

I
Research Activity

Concerns about internal exposure to low-dose radiation, which came to the fore immediately
after the Fukushima nuclear power plant accident that occurred following the Great East
Japan Earthquake, became a social issue. This concern ultimately boils down to the existenceor non-existence of carcinogenesis in the exposed generation and hereditary effects on thenext generation. In this context, genetic effects have not been observed in the vast amountof research conducted to date on the effects on the children of second-generation A-bomb
survivors (LSS and AHS) and Chernobyl nuclear power plant accident decontamination
workers, not only in phenotypic effects but also in DNA-level effects. Nonetheless, there
continues to be concern about heritable effects on second-generation A-bomb survivors andresidents of the Fukushima nuclear power plant accident. This is a worrisome situation that
could lead to a major trend toward genetic discrimination if concerns about genetic effects aresocially accepted. It is an urgent issue to minimize such concerns as much as possible.
The purpose of this study is to present statistically tolerable values of the radiation exposure
effects per generation due to internal exposure to Cesium-137 by whole DNA sequencingof liver cells of mice that have been drinking Cesium-137 (100 Bq/ml) water for multiple
generations. Note that although the experimental subjects are mice, the spontaneous mutation
rate of the next generation is almost the same as that of humans, and it is hoped that it will bepossible to predict in a short period of time what would take several hundred years in humans.
DNA was extracted from frozen samples of A/J mouse strains that were allowed to change
generations while drinking Cesium-137 water (100q/ml) for whole genome analysis. A total ofsix samples from the 25th generation (F20→F45), three each from the Cs-137 group and thecontrol group, were sent to RIKEN GENESIS for whole genome analysis using the Illumina
NovaSeq6000 with read length: 150, Paired-end, Multiplex method. The genomes were
statistically processed and compared with the previous 1, 2, 5, and 18 generations (n=1 foreach). The average testis dose was calculated to be 301 µGy/day using the PHITS code with amouse voxel phantom. The average dose per generation was calculated to be 32.5 mGy, and theaccumulated dose over a period of 25 generations was 812.5 mGy.
The correlation between the control and Cs-137 groups for each single nucleotide mutation
rate per 2,483,169,483 bases at generations 1, 2, 5, 18, and 25 was determined. The results
showed that the respective slopes were 0.167 and 0.167, the correlation coefficients were 0.977
and 0.979, and the coefficients of determination were 0.955 and 0.958. The frequency of DNA
single nucleotide variations between the two groups was almost the same over the generations.

19

IRS ANNUAL REPORT

2022

Non-destructive Determination of
Bulk elemental composition for asteroid Ryugu
by muon elemental analysis method
NINOMIYA, Kazuhiko;1* CHIU, I-Huan1 and Muon elemental analysis team
1 Institute for Radiation Sciences, Osaka University* ninomiya@rirc.osaka-u.ac.jp

A muon can make muon atomic orbit around nucleus due to its negative charge and form amuonic atom. After formation of a muonic atom, characteristic muonic X-rays (muonic X-rays)
are emitted by muon interorbital transition. Because the mass of the muon is approximately
207 times higher than that of an electron, the energies of muonic X-rays are much higher thanthese of electrons’. Such high energy X-rays can penetrate bulk material without absorption. In
recent, using muonic X-rays, non-destructive elemental analysis method has been developed [1].
This can identify elements including light ones such as carbon, nitrogen and oxygen, for bulk
material non-destructively. This method has already been applied to analysis of precious
meteorites and cultural heritage samples.

I
Research Activity

In this study, we applied muon elemental analysis method for the grains recovered from theasteroid Ryugu [2]. Asteroid Ryugu is a primitive asteroid classified as a C-type asteroid, which
retains information on the early solar system. The composition of carbon, nitrogen, and oxygen,
which are the most important materials for life, are attracting attention in such primitive
material. However, it is difficult to identify these light elements for bulk sample without sample
destruction except for muon elemental analysis method due to low energies of fluorescence
X-rays from these elements.
The muon experiment was conducted at the D2 experimental area in the muon science facility(MUSE) of J-PARC (Japan Proton Accelerator Research Complex, Ibraraki Pref.). A low
background muonic X-ray measuring system was developed for this study. We prepared 123 mg
of Ryugu sample for the analysis. Muonic X-rays emitted after muon irradiation on the sample
were measured by high-purity germanium detectors. For quantitative elemental analysis, we
also performed muon irradiation experiment under the same conditions for the carbonaceous
meteorites of Orgueil.
Figure 1 shows muonic X-ray spectra for Ryugu and Orgueil samples. The signals derived fromC, N, O, Na, Mg, Si, S, Fe, and Ni were identified, which means the main components of Ryugu
were these elements. The spectra obtained from the Ryugu and Orgueil samples were very
similar to each other. On the other hand, there
were clear differences between the Ryugu
and Orgueil samples; the intensity of O wasclearly lower for Ryugu than that of Orgueil.
The results of this study suggests that Orgueil
may have been contaminated by the Earth's
material such as water in the atmosphere.
Figure 1: Muonic X-ray spectra for Ryugu andOrgueil together with assigns of principle peaks.

References[1] NINOMIYA, K., Journal of Nuclear and Radiochemical Sciences, 2019, 19, 8-13.
[2] NAKAMURA, T.; et al., Science, 2022, 379, eabn8671.

IRS ANNUAL REPORT

2022

20

Oxidation of Cu-Au Alloy Surface by
Oxygen Molecular Beam
OKADA, Michio
Institute for Radiation Sciences, Osaka University* okada@chem.sci.osaka-u.ac.jp

Activation of molecular oxygen (O2) constitutes an important step in oxidative processes,
including heterogeneous catalysis, electrocatalysis, and corrosion of metals. The interaction of
O2 with various metal surfaces induces changes in its chemical stability and reactivity. It follows
that the ability to control such processes bears on the chemical economic world. Alloying ofpristine metals provides one of the simplest ways to do so. Understanding the microscopic
mechanism behind O2 chemisorption entails unraveling the stereochemistry of the processes
involved.

I
Research Activity

We report the stereochemistry of oxidation. The orientation and motion of reactants play
important roles in reactions. The small rotational excitations involved render the reactants
susceptible to dynamical steering, making direct comparison between experiments and theory
rather challenging. Using space-quantized molecular beams, we directly probed the (polar
and azimuthal) orientation dependence of O2 chemisorption on Cu(110) and Cu3Au(110). We
observed polar and azimuthal anisotropies on both surfaces. Chemisorption proceeded rather
favorably with the O–O bond axis oriented parallel (vs perpendicular) to the surface andrather favorably with the O–O bond axis oriented along [001] (vs along [1-10] ). The presenceof Au hindered the surface from further oxidation, introducing a higher activation barrier tochemisorption and rendering an almost negligible azimuthal anisotropy. The presence of Au
also prevented the cartwheel-like rotations of O2.

Fig.1. Oxidation of alloy surface by quantum controlled O2

Reference[1] TSUDA, Y.; GUERIBA, J.S.; UETA, H; DIÑO, W.A.; KURAHASHI, M.; OKADA, M, JACS Au 2022, 2, 1839-1847.
21

IRS ANNUAL REPORT

2022

Investigation of chemical purification
method for Ce-141 as candidate nuclide
for radiotheranostics
OOE, Kazuhiro;1* WATABE, Tadashi;2,3 SHIRAKAMI, Yoshifumi;3 NAMBU, Akihiro;4
HABA, Hiromitsu4 and HATAZAWA, Jun5
1 Radioisotope Research Center, Institute for Radiation Sciences, Osaka University
2 Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine
3 Institute for Radiation Sciences, Osaka University
4 Nishina Center for Accelerator-Based Science, RIKEN
5 Research Center for Nuclear Physics, Osaka UniversityI* ooe@rirc.osaka-u.ac.jp

Research Activity

One of the candidate radionuclides for theranostics (therapeutics + diagnosis) is cerium-141(141Ce, T1/2 = 32.5 d). This nuclide emits β-particles (maximum β energy: 580.7 keV), which canbe used for tumor therapy, and emits γ-rays with an energy of 145.4 keV, which can be used
for imaging by single photon emission computed tomography (SPECT). In addition, 141Ce canbe produced in the 138Ba(α,n)141Ce reaction using accelerators, leading to a stable domestic
supply in Japan. However, in nuclear medicine, 141Ce has rarely been used. In this study, weinvestigated the chemical purification method for 141Ce from the irradiated Ba target.
141

Ce was produced in the natBa(α, xn)141Ce reaction with a 29-MeV alpha beam using the
RIKEN K70 AVF Cyclotron. A natBaO pellet was used as a target material. The irradiatednat
BaO target (approximately 100 mg) was dissolved in 3 mL of 1 M HCl. After evaporation
to dryness, the residue was dissolved in 10 mL of 0.03 M HCl solution. The solution was
filled into a 10 mL syringe and then injected into the Ln resin cartridge column (extraction
chromatographic resin with di(2-ethylhexyl) phosphoric acid) at a flow rate of 1 drop per 1–2
seconds. Each 1 mL of the eluents was corrected with sample tubes. The natBa was washed out
from the cartridge with 0.03 M HCl, and then 141Ce was eluted with 1 M HCl solution. Each
eluted sample was subjected to γ-ray spectrometry with a Ge detector for the determination of141
Ce radioactivity. After measurement with the Ge detector, the concentration of natBa in eachsample was measured by ICP-MS.
The time required for the separation of 141Ce with the Ln resin cartridge was less than 1 hour.
Most of natBa was eluted at elution volume of around 15 mL with 0.03 M HCl. After elution ofnat
Ba, 141Ce was recovered by elution with 1 M HCl. The recovery yield for 141Ce was as highas 96%. The contamination of natBa in the 141Ce fractions was calculated to be approximately
0.6 μg in the ICP-MS measurement. The separation factor of 141Ce for Ba is estimated to beapproximately 105. In the next study, the radiopharmaceutical labeling of 141Ce using DOTA
(1,4,7,10-Tetraazacyclododecane- 1,4,7,10-tetraacetic Acid), which is widely used for chelatelabeling of therapeutic radionuclides, will be investigated.

IRS ANNUAL REPORT

2022

22

Synthesis and preclinical evaluation of
PSMA derivatives labeled with astatine-211
SHIRAKAMI, Yoshifumi;1,2* KANEDA-NAKASHIMA, Kazuko;1,2 WATABE, Tadashi;1,4
KADONAGA Yuichiro;4 OOE, Kazuhiro;1 KON, Yukiyoshi;1 HABA, Hiromitsu;5 YIN, Xiaojie;5
TOYOSHIMA, Atsushi1,2,3 and FUKASE, Koichi1,2,6
1 Institute for Radiation Sciences, Osaka University
2 MS-CORE, Forefront, Graduate School of Science, Osaka University
3 Research Center for Nuclear Physics, Osaka University
4 Graduate School of Medicine, Nuclear Medicine and Tracer Kinetics, Osaka University
5 Nishina Center for Accelerator-Based Science, RIKEN
6 Department of Chemistry, Graduate School of Science, Osaka UniversityI* yoshifumi_shirakami@irs.osaka-u.ac.jp

Research Activity

It is well known that prostate specific membrane antigen (PSMA) is an excellent target for PET
imaging and radiotherapy. Astatine-211 (211 At) is one of the promising radionuclides for alphaparticle targeted therapy. 211At-labeled products can be manufactured on site and on demand.
We synthesized an novel PSMA derivative labelled with 211At, [211At]PSMA5, for the targetedalpha therapy of metastatic prostate cancer (Fig.1).

211

Fig. 1 Chemical structure and radiolabeling scheme of [At]PSMA5

A PSMA precursor coupled with boronic acid, PSMA5, was synthesized and reacted withaqueous solutions of 211At in the presence of KI at 80℃ for 45 minutes. The reaction mixtures
were purified by a solid-phase extraction (SPE) method with Oasis HLB cartridges (Waters).
Radiochemical yields (RCY) and radiochemical purities (RCP) of the product were 84.7% and99.7%. The boron-astatine substitution reaction is the efficient method for 211At labeling of the
PSMA ligand. [211At]PSMA-5 are promising agent for the treatment of prostate cancer.

References[1] SHIRAKAMI, Y., WATABE, T., OBATA, H., KANEDA-NAKASHIMA, K., OOE, K., LIU, T., TERAMOTO, T.,
TOYOSHIMA, A., SHINOHARA, A., SHIMOSEGAWA, E., HATAZAWA, J., FUKASE, K., Sci. Reports 2021, 11:12982.
[2] CARDINAL, J., ROSCHER, M., SCHEFER, M., GEERLINGS, M. Benesova, M., BAUDER-WUST, U.,
REMDE, Y.,EDER, M., NOVAKOVA, Z., MOTLOVA, L., BARINKA, C., GIESEL, FL., KOPKA, K.,
J. Med. Chem. 2020, 63, 10897−10907.
23

IRS ANNUAL REPORT

2022

Project to collect accidents and incidents forthe creation of educational andtraining materials
SUZUKI, Tomokazu;1* HIGAKI, Shogo2 and TAKAHASHI, Masaomi3
1
2
3

Institute for Radiation Sciences, Osaka University
Isotope Science Center, University of Tokyo
The Department for the Administration of Safety and Health, Osaka University* tomokazu@rcnp.osaka-u.ac.jp

I
Research Activity

Act on the Regulation of Radioisotopes, etc. requires safety culture building activities in
response to the IAEA’s GSR Part 2, “Leadership and Management for Safety”. Specifically,
Article 38-4 of the Act stipulates that a user who holds the permission and a user who has
notified is responsible for improving duties, enhancing education and training, and taking othermeasures. Heinrich’s Law states that behind one major accident there are 29 minor accidental
disasters and thousands more potential troubles. Therefore, the collection of near-missinformation is an effective means of preventing major accidents by eliminating minor accidents
and potential problems one by one before they lead to a major accident.
In radiation control, “major accidents” in Heinrich’s Law are defined here as reportable
accidents as defined in Article 28-3 of the enforcement regulations. The number of major
accidents is very small, averaging about 4.5 per year from JFY2006 to JFY2020, and since thenumber of near-misses collected at a single RI site is very small, it is difficult to evaluate andimprove safety without obtaining information on near-misses that have occurred at other sites.
Therefore, sharing near-miss information among RI facilities would enable efficient safety
improvement activities. In the field of nuclear power, information on problems is made publicthrough NUCIA [1], an information disclosure library, but in the field of radiation application,
there is no database or even a mechanism.
With the support of Grant-in-Aid for Scientific Research from JFY2022, we launched a project
to collect information on near-misses in the field of radiation application in order to create
educational materials for sharing information on near-misses. In JFY2022, we conducted aquestionnaire survey and obtained information on about 75 near-miss events.
This work is supported by JSPS KAKENHI Grant Number JP22K029440.

Reference[1] NUCIA, Japan Nuclear Safety Institute; http://www.nucia.jp/

IRS ANNUAL REPORT

2022

24

Direct Detection of Gamma-Rays from
Laser Plasma
TAMII, Atsushi;1,2,3* IWASAKI, Ryota;3 KOBAYASHI, Nobuyuki;1 INOUE, Azusa;1
NIINA, Rei;1 OTA, Shinsuke;1 SUDO, Takashi;1 ROKUJO, Hiroki;4 NAKAZAWA, Kazuma;5,6
NISHIUCHI, Mamiko;7 SAKAKI, Hironao;7,8 KONDO, Kotaro;7 KON, Akira;7 LIU, Chang;7
KAWABATA, Takahiro;3 FURUNO, Tatsuya;3 TSUJI, Seiya;3 MIYAMOTO, Kenshin;3
HONDA, Yuya;3 NIIKURA, Megumi6 and WIELAND, Oliver9
1

Research Center for Nuclear Physics, Osaka University
Institute of Radiation Sciences Osaka University
Department of Physics, Faculty of Science, Osaka University
4
Fundamental Particle Physics Laboratory, Nagoya University
5
Faculty of Education, Gifu University
6
Nishina Center, RIKEN
7
Kansai Photon Science Institute, National Institutes for Quantum Science and Technology
8Interdisciplinary Graduate School of Engineering Sciences, Kyushu University
9
Department of Physics, University of TINFN, Sezione di Milano, Italy
2
3

I
Research Activity* tamii@rcnp.osaka-u.ac.jp

The project’s primary goal is to develop a technology for directly measuring emitted gammarays above 10 MeV from laser plasma using nuclear emulsion, that has not been achieved yet.
This research, aimed at understanding laser plasma dynamics and detecting nuclear reactions,is essential for global research on laser plasma diagnostic techniques.
Data analysis from a development experiment using the J-KAREN-P laser at the Kansai
Photon Science Institute in 2021 was advanced, primarily led by a graduate student at
Osaka University. A high-brilliance pulse-laser with an intensity of 1021 W/cm2 was fired on a
5 μm silver thin-film target. An emulsion detector, one meter from the target, was set up for
capturing gamma-rays. After the irradiation, the emulsion was developed and digitized at Gifu
and Nagoya University, respectively.
Through analysis, we confirmed four tracks of electron-positron pair generation linked to
gamma rays, with detected energy estimated at 39,45,46 and 76MeV. Simulation work is
ongoing to estimate the noises from gamma rays generated in the vacuum chamber. Preliminary
results were presented at OPTO2020, and a research paper is in progress.
In 2023, we aim to establish clearer evidence of gamma-ray detection from laser plasma using
an emulsion placed inside the vacuum chamber.

Reference[1] A. Tamii, R. Iwasaki et al., The Joint Symposium on Optical and Quantum Beam Science(OPTO2022), Kansai
Photon Science Institute, National Institutes for Quantum Science and Technology, June 28-29, 2022.
25

IRS ANNUAL REPORT

2022

Revealing ultrafast vibronic dynamics oftetracene molecules with
sub-8 fs UV impulsive Raman spectroscopy
TERAMOTO, Takahiro;1* LIU, Jun;2,3 DU, Juan2,4 and KOBAYASHI, Takayoshi5,61

Institute for Radiation Sciences, Osaka University
State Key Laboratory of High Field Laser Physics and CAS Centre for Excellence in Ultra-intense Laser Science,
Shanghai Institute of Optics and Fine Mechanics ( SIOM)
3
University Centre of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences
4
Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences
5
Advanced Ultrafast Laser Research Centre and Brain Science Inspired Science Support Centre, The University of Electro-Communications
6
Department of Electrophysics, National Chiao-Tung University
2

I* teramoto@irs.osaka-u.ac.jp

Research Activity

Ultrafast dynamics of tetracene molecules in THF solution were investigated using sub8 fs ultraviolet pulse lasers and ab initio calculations. The time trace of absorbance changes
exhibited ultrafast decay with a time constant of 165 ± 10 fs because of the relaxation froma vibronically hot excited state to the potential minimum in the S1 state. From the signals ofabsorbance changes in the negative time region, we obtained the electronic dephasing timeof 31.27 ± 1.63 fs. Inverse Fourier transform of stationary absorption spectra exhibited rapid
decay with 2.1 ± 0.08 fs. From these data, we estimated the ratio of total dephasing time tohomogenous and inhomogeneous broadening as 6.7% and 93.3%, respectively. Impulsive Raman
spectra ref lect the wave packet dynamics of vibrational modes. Although inhomogeneous
broadening blurred the phase jump across the resonance peak in the spectral range, 1156
and 1680 cm−1 vibrational modes exhibited a phase jump from −π to ~π and −0.5π to ~0.5π,
respectively. The amplitude profiles of these vibrational modes agree with simulated vibronic
progressions of combination bands. Time–frequency analysis revealed coupling dynamics
between low- and high-frequency modes, where high-frequency modes are in-plane motions
and low-frequency modes are out-of-plane motions. Therefore, these coupling dynamics induce
symmetry-breaking of the molecular framework, which fastens the singlet fission process.

Reference[1] TERAMOTO, T.; LIU,J.; DU, J.KOBAYASHI,T., Phys. Chem. Chem. Phys., 2022,24, 27783-27792.

IRS ANNUAL REPORT

2022

26

Targeted α-therapy using
astatine (211At)-labeled PSMA:a preclinical evaluation as a novel compound
WATABE, Tadashi;1,2* KANEDA-NAKASHIMA, Kazuko;2,4 SHIRAKAMI, Yoshifumi;2
KADONAGA, Yuichiro;1,2 OOE, Kazuhiro;2 TOYOSHIMA, Atsushi;2
GIESEL, Frederik L.;2,3 TOMIYAMA, Noriyuki1,2 and FUKASE, Koichi2,41Graduate School of Medicine, Osaka University
Institute for Radiation Sciences, Osaka University
Department of Nuclear Medicine, University Hospital Dusseldorf
4Graduate School of Science, Osaka University
2
3

I* watabe.tadashi.med@osaka-u.ac.jp

Research Activity

Prostate cancer is currently the most prevalent cancer among men in the world. Hormone
therapy is performed for recurrent lesions after surgery and radiation therapy, but the
prognosis is poor if hormone therapy become resistant with multiple metastases.
In recent years, attention has been paid to prostate-specific membrane antigen (PSMA), which
is a membrane marker expressed in prostate cancer. PSMA is expressed in more than 90% of
prostate cancers. We have succeeded in developing a new innovative therapeutic drug [211At]
PSMA5 targeting PSMA using the accelerator-manufacturable alpha-ray nuclide astatine(211At).
Preclinical evaluation using a prostate cancer model showed markedly high accumulation in
the tumor (30.6 ± 17.8 %ID/g at 3 h and 40.7 ± 2.6 %ID/g at 24 h, respectively). An excellent
tumor growth suppression was observed after [211At]PSMA5 administration (Fig.1). Currently,
attention is focused on PSMA treatment using another alpha-ray nuclide, actinium (225Ac), but
its production requires nuclear fuel material or rare radioisotopes, and its supply is extremely
limited. Targeted alpha therapy using [211At]PSMA5 resulted in excellent treatment effect ontumor growth with minimal side effects in the normal organs. [ 211At]PSMA5 can be a new
innovative therapy for metastatic castration-resistant prostate cancer.
This project was adopted for AMED translational research (seeds-F) during FY 2022-2026.
We have performed preclinical examinations to evaluate toxicity and biodistribution of [211At]
PSMA5 in rodents and non-rodents according to the PMDA consultation. Phase-I investigatorinitiated clinical trial will start in 2024.

fig.1. Antitumor effect of [ 211At]PSMA5 after single
administration in prostate cancer model mouse (left)
and biodistribution in tumor-bearing model (right):
High accumulation in tumor (arrow) can be confirmed.

Reference[1] WATABE, T.; Kaneda-Nakashima K.; Shirakami. Y; et al., Eur J Nucl Med Mol Imaging, 2023. Feb;50(3):849-858.
27

IRS ANNUAL REPORT

2022

Enrichment of 48Ca by Laser Isotope Separation
for the Study of Double Beta Decay
RITTIRONG, Anawat;1 YOSHIDA, Sei;2* UMEHARA, Saori;1*
OGAWA, Izumi3 and TOKITA, Shigeki4
1

Research Center for Nuclear Physics, Osaka University
Graduate School of Sciences, Osaka University
Graduate School of Engineering, Fukui University
4
Institute for Chemical Research, Kyoto University
2
3* sei@ne.phys.sci.osaka-u.ac.jp

I
Research Activity

CANDLES project searches for neutrino-less double beta(ββ) decay using 48Ca, which has
the highest Q-value of 4.27 MeV among the ββ decay nuclides. In the recent study by the
CANDLES III system, consisting of 96 nat.CaF2 scintillator crystals (0.35 kg of 48Ca), the lower
limit of the half-life of neutrino-less ββ decay of 5.6×1022 year (90% C.L.) was obtained by 21
selected high-purity crystals.[1] CANDLES III used natural calcium, which contains only 0.187%
of 48Ca. The isotope enrichment of 48Ca is required to improve the detector sensitivity. However,calcium has no gaseous compound, and industrial-scale isotope separation methods such as
gas diffusion and gas centrifuge are inapplicable. The only currently available method is theelectromagnetic separator, which has a low production yield and is much expensive (~1 M$/g).
We focus on the development of laser isotope separation (LIS). We conducted the proof-ofprinciple experiment. [2,3] The deflection laser was irradiated perpendicular to the calcium
atomic beam. The target calcium isotope absorbed the momentum of the incoming laser
photon, which has a stable (less than 2 MHz rms) continuous wave oscillation at a calcium
absorption wavelength of 422.792 nm and was deflected from the original atomic beam. The
separation of 48Ca and the calcium recovery were up to 5.5% and 19.6% at the deflection angleof 12.5 mrad, respectively. Toward the mass production of enriched 48Ca, the intense atomic
beam generator is being developed. The effect of the length of the single-tube collimator on theatomic beam shape was reported in Ref.[3]. The recovery system is also being developed to findthe most applicable material to be used as a collection plate. The small chamber was introduced
to expose the material to the calcium atomic beam. For future development, we installed the
new irradiation chamber consisting of 6 irradiation ports aiming to produce up to 2 mol/yearof 48Ca by the full operation of six ports. The first step is to get stable operation from one of
the six ports with the 2 W laser power. The atomic beam intensity and isotope fractionation
were measured by the time of flight (TOF) system. The collection system is designed to be
automated for 24-hour operation via the conveyor belt and the collection plate at the center ofthe chamber.

References[1] S. Ajimura, et al., Physical Review D103, no.9, 092008, 2021
[2] K. Matsuoka, H. Niki, I. Ogawa, Y. Shinki, Y. Kawashima, and K. Matsumura, Journal of Physics: Conference Series,
vol.1468, 012199, 2020.
[3] I. Ogawa, et al., Journal of Physics: Conference Series 2147, 012012, 2022.

IRS ANNUAL REPORT

2022

28

Synthesis of Octahedral Hexanuclear Rhenium
Complexes as a Molecular Targeted AgentNISHIZAWA, Hayato;1 NAGATA, Kojiro;2
KANEDA-NAKASHIMA, Kazuko1 and YOSHIMURA, Takashi*2
12

Graduate School of Science, Osaka University
Radioisotope Research Center, Institute for Radiation Sciences, Osaka University* tyoshi@rirc.osaka-u.ac.jp

Photodynamic therapy (PDT) is the method to damage cells using reactive oxygen species
generated by excitation of the chromophore and energy transfer to oxygen molecules. The
octahedral hexanuclear rhenium complex is known to show photoluminescence from theexcited triplet state with lifetime of microseconds. In addition, the complex shows high thermal
stability and low toxicity. Therefore, the complex has potential as a drug for PDT. In practice,
the previous study has reported that the toxicity of the octahedral hexanuclear complex was
examined when the complex was incorporated to cells and photo-irradiated. [1] There is no
study for the rhenium complexes actually being injected into cancer model mice to examine
accumulation in cancer tissue. In the present study, we synthesized the new complex with
4-(pyridyl)triazole-L-phenylalanine (ptph) which is potentially expectable to accumulate incancer cells.

I
Research Activity

The complex (n-Bu 4 N) 3 [Re 6 S 8 Cl 5 (tepy)] (tepy = 4-trimethylsilylethynylpyridine)
was synthesized and structurally characterized by single-crystal X-ray analysis. The
L-phenylalanine moiety was introduced in the rhenium complex by the reaction of N-Boc4-azido-L-phenylalanine methyl ester with (n-Bu 4N) 3[Re 6S 8Cl 5(tepy)] in the presence ofcopper catalyst to give (n-Bu4N)3[Re6S8Cl5(ptphMB)] (ptphMB = N-Boc-4-(pyridinetriazole)L-phenylalanine methyl ester). The complex, Na3[Re6S8Cl5(ptph)] was synthesized by themetathesis and deprotection of ptphMB in [Re6S8Cl5(ptphMB)]3-.
The complexes were characterized by 1H NMR and IR spectra. Two types of photoluminescenceswere observed for the complexes, originating from the cluster core-centered excited triplet
state (3CC) for Na3[Re6S8Cl5(ptph)], and from the metal-to-ligand charge-transfer excitedtriplet state (3MLCT) for (n-Bu4N)3[Re6S8Cl5(tepy)] and (n-Bu4N)3[Re6S8Cl5(ptphMB)]. The
emission intensity and emission quantum yield and emission lifetime of Na3[Re6S8Cl5(ptph)]
was decreased in the presence of oxygen, indicating that the energy transfer from the excitedcomplex to oxygen molecules was occurred to generate oxygen molecules with spin singlet
states.
The LD50 values of Cs4[Re6S8Cl6]·CsCl and Na3[Re6S8Cl5(ptph)] were similar to those of thecomplexes previously reported. The cell viability in dark and under irradiation of visible
light was investigated. The cell viabilities under irradiation of light were lowered than thosein dark for both Cs4[Re6S8Cl6]·CsCl and Na3[Re6S8Cl5(ptph)]. When the Cs4[Re6S8Cl6]·CsCland Na 3 [Re 6 S 8 Cl 5 (ptph)] were injected into cancer model mice, the %ID values of
Cs4[Re6S8Cl6]·CsCl and Na3[Re6S8Cl5(ptph)] were 4.5±2.8% and 9.0±8.3%, respectively, after
3 h from injection of the complexes.
Reference[1] A. O. Solovieva, K. Kirakci, A. A. Ivanov, P. Kubát, T. N. Pozmogova, S. M. Miroshnichenko, E. V. Vorontsova, A. V.
Chechushkov, K. E. Trifonova, M. S. Fufaeva, E. I. Kretov, Y. V. Mironov, A. F. Poveshchenko, K. Lang, M. A.
Shestopalov, Inorg. Chem. 56, 21, 13491-13499 (2017).
29

IRS ANNUAL REPORT

2022

AchievementsII

IRS ANNUAL REPORT

2022

30

Original Papers
O-1

Boron Delivery to Brain Cells via Cerebrospinal Fluid (CSF) Circulation in
BNCT of Brain-Tumor-Model Rats-Ex Vivo Imaging of BPA Using
MALDI Mass Spectrometry Imaging
Sachie Kusaka, Yumi Miyake, Yugo Tokumaru, Yuri Morizane, Shingo Tamaki, Yoko Akiyama,
Fuminobu Sato, Isao MurataLife 12 1786 (2022)

O-2

Cerebrospinal fluid-based boron delivery system may help increase
the uptake boron for boron neutron capture therapy inveterinary medicine: A preliminary study with normal rat brain cells

Sachie Kusaka, Yuri Morizane, Yugo Tokumaru, Shingo Tamaki, Indah Rosidah Maemunah, Yoko Akiyama,
Fuminobu Sato, Isao Murata
Research in Veterinary Science 148 1-6 (2022)
O-3

Study on irradiation effect of insulating materials for fusion superconducting
magnets-interlaminar shear strength at liquid helium temperature
Yoko Akiyama, Nobuto Akazawa, Yuta Kunitoku, Yuichiro Manabe, Fuminobu Sato, Akifumi Iwamoto,Shinsaku Imagawa, Shigehiro Nishijima
RADIATION PHYSICS AND CHEMISTRY 199 110372 (2022)

O-4

Study on Irradiation Effect of Insulating Materials for
Fusion Superconducting Magnet: Effect of Low-temperature Irradiation
Y Kunitoku, Y Akiyama, Y Manabe, F Sato
IOP Conference Series: Materials Science and Engineering 1241 12004 (2022)

O-5

Boron Delivery to Brain Cells via Cerebrospinal Fluid (CSF) Circulation for
BNCT in a Rat Melanoma Model

Sachie Kusaka, Yuri Morizane, Yugo Tokumaru, Shingo Tamaki, Indah Rosidah Maemunah, Yoko Akiyama,
Fuminobu Sato, Isao MurataLife 12 1786 (2022)
O-6

III

Radioactivation Analysis of Concrete Wall in OKTAVIAN Facility

Achievements

Shingo Tamaki, Fajar Panuntun, Kazumichi Uedoi, Wang Haidong, Sachie Kusaka, Yuichiro Manabe, Yoko Akiyama,
Teruya Tanaka, Fuminobu Sato, Isao Murata
Plasma and Fusion Research 17 1450001 (2022)
O-7

Triplet–Triplet Annihilation via the Triplet Channel in
Crystalline 9,10-Diphenylanthracene

Tomoaki Yago, Manami Tashiro, Kiichi Hasegawa, Masao Gohdo, Syuta Tsuchiya, Tadaaki Ikoma,Masanobu Wakasa
The Journal of Physical Chemistry Letters 13 8768-8774 (2022)
O-8

Direct ionization-driven observational approaches for radical cation formation
insolution for pulse radiolysis
Masao Gohdo, Seiichi Tagawa,Koichi Kan, Jinfeng Yang, Yoichi Yoshida
Radiation Physics and Chemistry 196 110105 (2022)

O-9

3D reconstructed brain images reveal the possibility of the ogg1 gene to suppress
the irradiation-induced apoptosis in embryonic brain in medaka (Oryzias latipes)
Takako Yasuda, Duolin Li, Erge Sha, Fumitaka Kakimoto, Hiroshi Mitani, Hiroshi Yamamoto,
Tomoko Ishikawa-Fujiwara, Takeshi Todo, Shoji Oda
Journal of radiation research 63 319-330 (2022)

O-10

Astatine-211-Labeled Gold Nanoparticles forTargeted Alpha-Particle Therapy via Intravenous Injection

Xuhao Huang, Kazuko Kaneda-Nakashima, Yuichiro Kadonaga, Kazuya Kabayama, Atsushi Shimoyama,Kazuhiro Ooe, Hiroki Kato, Atsushi Toyoshima, Atsushi Shinohara, Hiromitsu Haba, Yang Wang, Koichi Fukase
Pharmaceutics 14 2705 (2022)
O-11

Limonoids with anti-inflammatory activity: A review.

Erina Hilmayanti, Nurlelasari, Unang Supratman, Kazuya Kabayama, Atsushi Shimoyama, Koichi Fukase
Phytochemistry 204 113469 (2022)
O-12

Mechanistic Studies for the Rational Design of Multivalent Glycodendrimers

Yoshiyuki Manabe, Masato Tsutsui, Kohtaro Hirao, Risako Kobayashi, Hiroshi Inaba, Kazunori Matsuura,
Daisuke Yoshidome, Kazuya Kabayama, Koichi Fukase
Chemistry – A European Journal 28 e202201848 (2022)

31

IRS ANNUAL REPORT

2022

O-13

Precise immunological evaluation rationalizes the design of a self-adjuvanting
vaccine composed of glycan antigen, TLR1/2 ligand, and T-helper cell epitope
Tsung Che Chang, Yoshiyuki Manabe, Keita Ito, Ryuku Yamamoto, Kazuya Kabayama, Shino Ohshima,
Yoshie Kametani, Yukari Fujimoto, Chun Cheng Lin, Koichi Fukase
RSC Advances 12 18985-18993 (2022)

O-14

核医学装置における精度管理と性能評価のためのファントムスタディ
神谷 貴史, 佐々木 秀隆
日本放射線技術学会誌 78 753-759

O-15

SPECT画像における洗い出し率算出― 123I-BMIPP を用いた中性脂肪蓄積心筋血管症の診断基準 ―神谷 貴史
日本心臓核医学学会誌 25 18985-18993 (2022)

O-16

Mathematical Model for Evaluation of Tumor Response in
Targeted Radionuclide Therapy with 211At Using Implanted Mouse Tumor

Yoshiharu Yonekura, Hiroshi Toki, Tadashi Watabe, Kazuko Kaneda-Nakashima, Yoshifumi Shirakami,
Kazuhiro Ooe, Atsushi Toyoshima, Hiroo Nakajima, Noriyuki Tomiyama, Masako Bando
International Journal of Molecular Sciences 23 15966 (2022)
O-17

Effect to Therapy of Sodium-Iodine Symporter Expression
by Alpha-Ray Therapeutic Agent via Sodium/Iodine Symporter

Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Tadashi Watabe, Kazuhiro Ooe, Takashi Yoshimura,
Atsushi Toyoshima, Yang Wang, Hiromitsu Haba, Koichi FukaseInternational journal of molecular sciences 23 15509 (2022)
O-18

Substrate Study for Dihydroxyboryl Astatine Substitution Reaction with
Fibroblast Activation Protein Inhibitor (FAPI)

Ayaka Aso, Kazuko Kaneda-Nakashima, Hinako Nabetani, Yuichiro Kadonaga, Yoshifumi Shirakami,
Tadashi Watabe, Taku Yoshiya, Masayoshi Mochizuki, Yuki Koshino, Kazuhiro Ooe, Atsuko Kawakami,
Naoya Jinno, Atsushi Toyoshima, Hiromitsu Haba, Yang Wang, Jens Cardinale, Frederik L. Giesel,
Atsushi Shimoyama, Koichi Fukase
Chemistry Letters 51 1091 1094 (2022)

Targeted α-therapy using astatine ( At)-labeled PSMA1, 5, and 6:
a preclinical evaluation as a novel compound

Achievements

O-19

III

211

Tadashi Watabe, Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Yuichiro Kadonaga, Kazuhiro Ooe, Yang Wang,
Hiromitsu Haba, Atsushi Toyoshima, Jens Cardinale, Frederik L Giesel, Noriyuki Tomiyama, Koichi Fukase
Eur J Nucl Med Mol Imaging 50 849-858 (2022)
O-20

Dioxetane derivative containing carboxy group asa chemiluminophore-introducing reagent

Yukie Nohara, Shun Masuda, Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Masakatsu Matsumoto, Taku Yoshiya
Chembiochem : a European journal of chemical biology 23 e202200556 (2022)
O-21

Comparison of the Therapeutic Effects of [211At]NaAt and [131I]NaI in
an NIS-Expressing Thyroid Cancer Mouse Model

Tadashi Watabe, Yuwei Liu, Kazuko Kaneda-Nakashima, Tatsuhiko Sato, Yoshifumi Shirakami,
Kazuhiro Ooe, Atsushi Toyoshima, Eku Shimosegawa, Yang Wang, Hiromitsu Haba, Takashi Nakano,Atsushi Shinohara, Jun Hatazawa
International Journal of Molecular Sciences 23 9434 (2022)
O-22

Effects of film thickness and alkaline concentration on dissolution kinetics ofpoly (4-hydroxystyrene) in alkaline aqueous solution

Naoki Tanaka, Kyoko Matsuoka, Takahiro Kozawa , Takuya Ikeda, Yoshitaka Komuro and Daisuke Kawana
Jpn. J. Appl. Phys. 61 SD1016 (2022)
O-23

Effect of surface free energy of organic underlayer on dissolution kinetics ofpoly (4-hydroxystyrene) film in tetramethylammonium hydroxide aqueous developer
Tomoe Otsuka, Yuqing Jin, Naoki Tanaka, and Takahiro KOZAWA
Jpn. J. Appl. Phys. 61 056503 (2022)

O-24

Interdomain Electron Transfer in Flavohemoglobin from Candida norvegensis with
Antibiotic Azole Compounds
Kazuo Kobayashi, Jotaro Igarashi, and Takahiro Kozawa
FEBS Letters 596 938-946 (2022)

IRS ANNUAL REPORT

2022

32

O-25

Classification of lines, spaces, and edges of resist patterns inscanning electron microscopy images using unsupervised machine learning
Yuqing Jin and Takahiro Kozawa
Jpn. J. Appl. Phys. 61 56505 (2022)

O-26

Estimation of effective reaction radius for catalytic chain reaction ofchemically amplified resist by Bayesian optimization
Yuqing Jin and Takahiro Kozawa
Jpn. J. Appl. Phys. 61 66504 (2022)

O-27

Study on deprotonation from radiation-induced ionized acrylate polymers including
acid-generation promoters for improving chemically amplified resists
Kazumasa Okamoto, Akihiro Konda, Yuki Ishimaru, Takahiro Kozawa,
Yasunobu Nakagawa and Masamichi Nishimura
Jpn. J. Appl. Phys. 61 66505 (2022)

O-28

Sensitization mechanism of metal oxide nanocluster resists with carboxylic acid ligands
Tomoe Otsuka, Yusa Muroya, Takuya Ikeda, Yoshitaka Komuro, Daisuke Kawana and Takahiro Kozawa
Jpn. J. Appl. Phys. 61 86508 (2022)

O-29

Interfacial effects on sensitization of chemically amplified extreme ultraviolet resists
Takahiro Kozawa
Jpn. J. Appl. Phys. 61 116501 (2022)

O-30

Extended X-ray absorption fine structure spectroscopy measurements andab initio molecular dynamics simulations reveal the hydration structure of
the radium(II) ion

Akiko Yamaguchi, Kojiro Nagata, Keita Kobayashi, Kazuya Tanaka, Tohru Kobayashi, Hajime Tanida,
Kojiro Shimojo, Tetsuhiro Sekiguchi, Yui Kaneta, Shohei Matsuda, Keiichi Yokoyama, Tsuyoshi Yaita,
Takashi Yoshimura, Masahiko Okumura, Yoshio Takahashi
iScience 25 104763 (2022)
O-31

III
Achievements

Tuning the Ground- and Excited-State Redox Potentials ofOctahedral Hexanuclear Rhenium(III) Complexes by the Combination ofTerminal Halide and N-Heteroaromatic Ligands
Takashi Yoshimura, Hayato Nishizawa, Kojiro Nagata, Akitaka Ito, Eri Sakuda, Shoji Ishizaka,
Noboru Kitamura, Atsushi Shinohara
ACS Omega 7 26965-26982 (2022)

O-32

Development of Nondestructive Elemental Analysis System for
Hayabusa2 Samples Using Muonic X-rays

Takahito Osawa, Shunsaku Nagasawa, Kazuhiko Ninomiya, Tadayuki Takahashi, Tomoki Nakamura,
Taiga Wada, Akihiro Taniguchi, Izumi Umegaki, Kenya M. Kubo, Kentaro Terada, I-Huan Chiu, Shinichiro Takeda,
Miho Katsuragawa, Takahiro Minami, Shin Watanabe, Toshiyuki Azuma, Kazumi Mizumoto, Go Yoshida,
Soshi Takeshita, Motonobu Tampo, Koichiro Shimomura, Yasuhiro Miyake
ACS Earth and Space Chemistry 7 699-711 (2023)
O-33

The non-destructive investigation ofa late antique knob bow fibula (Bügelknopffibel)
from Kaiseraugst/CH using Muon Induced X-ray Emission (MIXE)
Sayani Biswas, Isabel Megatli-Niebel, Lilian Raselli, Ronald Simke, Thomas Elias Cocolios, Nilesh Deokar,
Matthias Elender, Lars Gerchow, Herbert Hess, Rustem Khasanov, Andreas Knecht, Hubertus Luetkens,
Kazuhiko Ninomiya, Angela Papa, Thomas Prokscha, Peter Reiter, Akira Sato, Nathal Severijns, Toni Shiroka,
Michael Seidlitz, Stergiani Marina Vogiatzi, Chennan Wang, Frederik Wauters, Nigel Warr, Alex Amato
Heritage Science 11:43 (2023)

O-34

Negative muon spin rotation and relaxation on Li metal

Jun Sugiyama, Izumi Umegaki, Soshi Takeshita, Takehito Nakano, Kazuhiko Ninomiya,
Koichiro Shimomura, M. Kenya Kubo
Journal of Physics: Conference Series 2462 12045 (2023)

33

IRS ANNUAL REPORT

2022

O-35

Formation and evolution of carbonaceous asteroid Ryugu:
Direct evidence from returned samples

T. Nakamura, M. Matsumoto, K. Amano, Y. Enokido, M. E. Zolensky, T. Mikouchi, H. Genda, S. Tanaka, M. Y. Zolotov,
K. Kurosawa, S. Wakita, R. Hyodo, H. Nagano, D. Nakashima, Y. Takahashi, Y. Fujioka, M. Kikuiri, E. Kagawa,
M. Matsuoka, A. J. Brearley, A. Tsuchiyama, M. Uesugi, J. Matsuno, Y. Kimura, M. Sato, R. E. Milliken, E. Tatsumi,
S. Sugita, T. Hiroi, K. Kitazato, D. Brownlee, D. J. Joswiak, M. Takahashi, K. Ninomiya, T. Takahashi, T. Osawa,
K. Terada, F. E. Brenker, B. J. Tkalcec, L. Vincze, R. Brunetto, A. Aléon-Toppani, Q. H. S. Chan, M. Roskosz,
J.-C. Viennet, P. Beck, E. E. Alp, T. Michikami, Y. Nagaashi, T. Tsuji, Y. Ino, J. Martinez, J. Han, A. Dolocan, R. J. Bodnar,
M. Tanaka, H. Yoshida, K. Sugiyama, A. J. King, K. Fukushi, H. Suga, S. Yamashita, T. Kawai, K. Inoue, A. Nakato,
T. Noguchi, F. Vilas, A. R. Hendrix, C. Jaramillo-Correa, D. L. Domingue, G. Dominguez, Z. Gainsforth, C. Engrand,
J. Duprat, S. S. Russell, E. Bonato, C. Ma, T. Kawamoto, T. Wada, S. Watanabe, R. Endo, S. Enju, L. Riu, S. Rubino,
P. Tack, S. Takeshita, Y. Takeichi, A. Takeuchi, A. Takigawa, D. Takir, T. Tanigaki, A. Taniguchi, K. Tsukamoto, T. Yagi,
S. Yamada, K. Yamamoto, Y. Yamashita, M. Yasutake, K. Uesugi, I. Umegaki, I. Chiu, T. Ishizaki, S. Okumura, E. Palomba,
C. Pilorget, S. M. Potin, A. Alasli, S. Anada, Y. Araki, N. Sakatani, C. Schultz, O. Sekizawa, S. D. Sitzman, K. Sugiura,
M. Sun, E. Dartois, E. De Pauw, Z. Dionnet, Z. Djouadi, G. Falkenberg, R. Fujita, T. Fukuma, I. R. Gearba, K. Hagiya,
M. Y. Hu, T. Kato, T. Kawamura, M. Kimura, M. K. Kubo, F. Langenhorst, C. Lantz, B. Lavina, M. Lindner, J. Zhao,
B. Vekemans, D. Baklouti, B. Bazi, F. Borondics, S. Nagasawa, G. Nishiyama, K. Nitta, J. Mathurin, T. Matsumoto,I. Mitsukawa, H. Miura, A. Miyake, Y. Miyake, H. Yurimoto, R. Okazaki, H. Yabuta, H. Naraoka, K. Sakamoto,S. Tachibana, H. C. Connolly, D. S. Lauretta, M. Yoshitake, M. Yoshikawa, K. Yoshikawa, K. Yoshihara, Y. Yokota,
K. Yogata, H. Yano, Y. Yamamoto, D. Yamamoto, M. Yamada, T. Yamada, T. Yada, K. Wada, T. Usui, R. Tsukizaki,
F. Terui, H. Takeuchi, Y. Takei, A. Iwamae, H. Soejima, K. Shirai, Y. Shimaki, H. Senshu, H. Sawada, T. Saiki, M. Ozaki,
G. Ono, T. Okada, N. Ogawa, K. Ogawa, R. Noguchi, H. Noda, M. Nishimura, N. Namiki, S. Nakazawa, T. Morota,
A. Miyazaki, A. Miura, Y. Mimasu, K. Matsumoto, K. Kumagai, T. Kouyama, S. Kikuchi, K. Kawahara, S. Kameda,
T. Iwata, Y. Ishihara, M. Ishiguro, H. Ikeda, S. Hosoda, R. Honda, C. Honda, Y. Hitomi, N. Hirata, N. Hirata, T. Hayashi,
M. Hayakawa, K. Hatakeda, S. Furuya, R. Fukai, A. Fujii, Y. Cho, M. Arakawa, M. Abe, S. Watanabe, Y. Tsuda
Science 379 eabn8671 (2022)
O-36

Non-Destructive Composition Identification for Mixtures of Iron Compounds
Using a Chemical Environmental Effect on a Muon Capture Process

Kazuhiko Ninomiya, Meito Kajino, Akihiro Nambu, Makoto Inagaki, Takuto Kudo, Akira Sato, Kentaro Terada,
Atsushi Shinohara, Dai Tomono, Yoshitaka Kawashima, Yoichi Sakai, Tsutomu Takayama
Bulletin of the Chemical Society of Japan 95 1769-1774 (2022)
O-37

Negative Muon Spin Rotation and Relaxation Study on Battery Anode Material,
Spinel Li4Ti5O12
Izumi Umegaki, Kazuki Ohishi, Takehito Nakano, Shoichiro Nishimura, Soshi Takeshita, Akihiro Koda,
Kazuhiko Ninomiya, M. Kenya Kubo, Jun Sugiyama
The Journal of Physical Chemistry C 126 10506-10514 (2022)

Achievements

O-38

III

VEGF (vascular endothelial growth factor) provides antimicrobial effects
via autophagy and lysosomal empowerment in endothelial cells
Shiou-Ling Lu, Takeshi Noda
Autophagy Reports 1 218 (2022)

O-39

VEGF-Mediated Augmentation of Autophagic and Lysosomal Activity inEndothelial Cells Defends against Intracellular Streptococcus pyogenes

Shiou-Ling Lu, Hiroko Omori, Yi Zhou, Yee-Shin Lin, Ching-Chuan Liu, Jiunn-Jong Wu, Takeshi Noda
mBio 13 e0123322 (2022)
O-40

Probing Copper and Copper–Gold Alloy Surfaces withSpace-Quantized Oxygen Molecular BeamYasutaka Tsuda, Jessiel Siaron Gueriba, Hirokazu Ueta, Wilson Agerico Diño, Mitsunori Kurahashi, Michio Okada
JACS Au 2 1839-1847 (2022)
O-41

Microstructure and Solute Segregation around the Melt‐Pool Boundary ofOrientation‐Controlled 316L Austenitic Stainless Steel Produced by Laser
Powder Bed Fusion
Kazuhisa Sato, Shunya Takagi, Satoshi Ichikawa, Takuya Ishimoto, Takayoshi Nakano
Materials 16 218 (2022)

O-42

Structural Defects and Ferromagnetic Signature ofV-Doped Sb2Te3 Thin Films
Grown on SrTiO3 (001) Produced by RF-Magnetron Sputtering
Kazuhisa SatoACS Omega 7 40480-40484 (2022)

O-43

Comparison of magnetic anisotropy and structural properties inchemically ordered CoPt and FePt nanoparticles

A. Tamion, F. Tournus, N. Blanc, A. Hillion, O. Proux, A. Rogalev, F. Wilhelm, J. Gutiérrez Valdés, L. E. Díaz-Sánchez,
K. Sato, G. M. Pastor, V. Dupuis
Physical Review B 106 104420 (2022)
IRS ANNUAL REPORT

2022

34

O-44

Stacking Faults and Intercalants in (Ta1–xTix)Se2 Revealed by
Cross-Sectional Transmission Electron Microscopy
Kazuhisa Sato,Toshiya Matsushita
The Journal of Physical Chemistry C 126 14290 (2022)

O-45

Excellent strength–ductility balance of Sc-Zr-modified Al–Mg alloy bytuning bimodal microstructure via hatch spacing in laser powder bed fusion

Yusufu Ekubaru, Ozkan Gokcekaya, Takuya Ishimoto, Kazuhisa Sato, Koki Manabe, Pan Wang, Takayoshi Nakano
Materials & Design 221 110976 (2022)
O-46

Damping of the isovector giant dipole resonance in Ca-40,Ca-48

J. Carter, L. M. Donaldson, H. Fujita, Y. Fujita, M. Jingo, C. O. Kureba, M. B. Latif, E. Litvinova, F. Nemulodi,
P. Von Neumann-Cosel, R. Neveling, P. Papakonstantinou, P. Papka, L. Pellegri, V. Yu Ponomarev, A. Richter, R. Roth,
E. Sideras-Haddad, F. D. Smit, J. A. Swartz, A. Tamii, R. Trippel, I. T. Usman, and H. Wibowo
Physics Letters B 833 137374 (2022)
O-47

Fast Heavy-Ion-Induced Anion–Molecule Reactions on the Methanol Droplet Surface
Takuya Majima, Yuki Mizunami, Takahiro Teramoto, Hidetsugu Tsuchida, Manabu Saito
The Journal of Physical Chemistry A 126 8988-8996 (2022)

O-48

Revealing ultrafast vibronic dynamics oftetracene molecules with sub-8 fs UV impulsive Raman spectroscopy
Takahiro Teramoto, Jun Liu, Juan Du, Takayoshi Kobayashi
Physical Chemistry Chemical Physics 24 27783-27792 (2022)

O-49

Wide-band X-ray and gamma-ray imaging ofliving mouse toreveal pharmacokinetics of At-211

M. Masubuchi, A. Omata, N. Koshikawa, J. Kataoka, H. Kato, A. Toyoshima, K. Ooe, D. Katayama, T. Teramoto,
K. Matsunaga, T. Kamiya, T. Watabe, E. Shimosegawa, J. Hatazawa
Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors andAssociated Equipment 1045 167581 (2023)
O-50

III

Ultrafast X-ray photoelectron diffraction from free molecules: Simulations ofdiffraction profiles from transient intermediates in the elimination reaction of C2H4I2

Achievements

S. Minemoto, J.H. Mun, T. Teramoto, A. Yagishita, S. Tsuru
Journal of Electron Spectroscopy and Related Phenomena 258 147221 (2022)
O-51

Ultrafast Excited State Dynamics of Forward and Reverse trans-cis
Photoisomerization of Red-Light-Absorbing Indigo Derivatives
Yu Kihara, Shuntaro Tani, Yamato Higashi, Takahiro Teramoto, Yutaka Nagasawa
The Journal of Physical Chemistry B 126 3539-3550 (2022)

O-52

Basic studies toward ultrafast soft x-ray photoelectron diffraction
its application to probing local structure in iodobenzene molecules

T. Teramoto, S. Minemoto, T. Majima, T. Mizuno, J. H. Mun, A. Yagishita, P. Decleva, S. Tsuru
Structural Dynamics 9 24303 (2022)
O-53

Advantages of FBPA PET in evaluating early response of anti-PD-1 immunotherapy in
B16F10 melanoma-bearing mice: Comparison to FDG PET
Mitsuaki Tatsumi, Fumihiko Soeda, Sadahiro Naka, Kenta Kurimoto, Kazuhiro Ooe, Hideyuki Fukui,
Daisuke Katayama, Tadashi Watabe, Hiroki Kato, Noriyuki Tomiyama
Frontiers in Oncology 12 (2022)

O-54

Celebrating 80 years anniversary of radioiodine for use in thyroid cancer andperspectives for theranostics
Hertz B, Watabe T, Baum RP
Annals of nuclear medicine 36 1007-1009 (2022)

O-55

Diagnostic and prognostic significance of tartrate-resistant acidphosphatase type 5b in newly diagnosed prostate cancer with bone metastasis:
A real-world multi-institutional study

Gaku Yamamichi, Taigo Kato, Satoru Yumiba, Eisuke Tomiyama, Yoko Koh, Kosuke Nakano, Makoto Matsushita,
Yujiro Hayashi, Yu Ishizuya, Tadashi Watabe, Koji Hatano, Atsunari Kawashima, Takeshi Ujike, Yutaka Ono,
Tsuyoshi Takada, Shingo Takada, Ryoichi Imamura, Norio Nonomura, Motohide Uemura
International journal of urology : official journal of the Japanese Urological Association 30 70-76 (2023)

35

IRS ANNUAL REPORT

2022

O-56

Neurovascular Uncoupling: Multimodal Imaging Delineates the Acute Effects of
3,4-Methylenedioxymethamphetamine
Tudor Mihai Ionescu, Mario Amend, Tadashi Watabe, Jun Hatazawa, Andreas Maurer, Gerald Reischl,
Bernd J Pichler, Hans F Wehrl, Kristina Herfert
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 64 466-471 (2023)

O-57

Development of artificial intelligence for automated measurement ofcervical lordosis on lateral radiographs

Takahito Fujimori, Yuki Suzuki, Shota Takenaka, Kosuke Kita, Yuya Kanie, Takashi Kaito, Yuichiro Ukon,
Tadashi Watabe, Nozomu Nakajima, Shoji Kido, Seiji Okada
Scientific reports 12 15732 (2022)
O-58

Semiquantitative analysis using whole-body dynamic F-18
fluoro-2-deoxy-glucose–positron emission tomography to differentiate
between benign and malignant lesions

Mirei Watanabe, Hiroki Kato, Daisuke Katayama, Fumihiko Soeda, Keiko Matsunaga, Tadashi Watabe,
Mitsuaki Tatsumi, Eku Shimosegawa, Noriyuki Tomiyama
Annals of Nuclear Medicine 36 951-963 (2022)
O-59

Response to the letter to the editor
Tadashi Watabe
Annals of nuclear medicine 36 844-844 (2022)

O-60

Efficacy of Combination Therapy with Lenvatinib and Radioactive Iodine in
Thyroid Cancer Preclinical Model

Kensuke Suzuki, Hiroshi Iwai, Keita Utsunomiya, Yumiko Kono, Tadashi Watabe, Yoshiki Kobayashi, Dan Van Bui,
Shunsuke Sawada, Yasutaka Yun, Akitoshi Mitani, Kenta Fukui, Haruka Sakai, Hanh Hong Chu, Nguyen Manh Linh,
Noboru Tanigawa, Akira Kanda
International journal of molecular sciences 23 9872 (2022)
O-61

Investigator-Initiated Clinical Trial of 211At-NaAt against Refractory Thyroid Cancer

Tadashi Watabe
Gan to kagaku ryoho. Cancer & chemotherapy 49 829-834 (2022)
O-62

III
Achievements

Usefulness of positron-emission tomography for predicting the World HealthOrganization grade of thymic epithelial tumors
Takashi Kanou, Soichiro Funaki, Masato Minami, Naoko Ose, Toru Kimura, Eriko Fukui,
Tadashi Watabe , Yasushi Shintani
Thoracic cancer 13 1651-1656 (2022)

O-63

Improved Stability and Practicality for Synthesis of
4-Borono-2-[18F]fluoro-l-phenylalanine by Combination of[18O]O2 Single-Use and [18F]CH3COOF Labeling Agents

Sadahiro Naka, Toshimitsu Watanabe, Yasukazu Kanai, Tadashi Watabe, Mitsuaki Tatsumi,
Hiroki Kato,Eku Shimosegawa, Jun Hatazawa
Nuclear medicine and molecular imaging 56 86-95 (2022)

O-64

Oligometastatic Lymph Node Recurrence Detected Using 18F-PSMA-1007 PET/CT ina Patient With Castration-resistant Prostate Cancer After Radiation Therapy
Shunsuke Mori, Taigo Kato, Tadashi Watabe, Koji Hatano, Toyohumi Abe, Shinichiro Fukuhara, Hiroshi Kiuchi,
Ryoichi Imamura, Motohide Uemura, Norio Nonomura
Cancer diagnosis & prognosis 2 598-602 (2022)

O-65

Case report: Transplantation of human induced pluripotent stem cell-derived
cardiomyocyte patches for ischemic cardiomyopathy

Shigeru Miyagawa, Satoshi Kainuma, Takuji Kawamura, Kota Suzuki, Yoshito Ito, Hiroko Iseoka, Emiko Ito,
Maki Takeda, Masao Sasai, Noriko Mochizuki-Oda, Tomomi Shimamoto, Yukako Nitta, Hiromi Dohi,
Tadashi Watabe, Yasushi Sakata, Koichi Toda, Yoshiki Sawa
Frontiers in cardiovascular medicine 9 950829 (2022)
O-66“ニュートリノを伴わない二重ベータ崩壊”で宇宙の謎を探る”
梅原 さおり, 吉田 斉
日本物理学会誌 77 514-522 (2022)

IRS ANNUAL REPORT

2022

36

Biblios
B-1

量子ビーム科学の基礎と応用

永宮 正治編, 民井 淳, 小沢 恭一郎, 前川 藤夫, 羽場 宏光, 吉田 敦, 阿部 知子, 郡司 卓, 後田 裕, 中村 哲, 柴山 充弘,
三宅 康博, 田村 裕和, 中家 剛, 櫻井 博儀, 石川 哲也, 中野 隆史, 若月 優, 櫻井 英幸, 水本 斉志, 中野 貴志, 渡部 直史,
白神 宜史, 渡部 浩司, 福田 光宏, 豊嶋 厚史, 熊田 博明, 髙橋 忠幸著
一般社団法人日本原子力産業協会 (2023)

B-2

α線核医学治療の大阪大学における取り組み
樺山 一哉, 白神 宜史, 兼田 加珠子, 渡部 直史, 豊嶋 厚史

MEDCHEM NEWS 32 93-98 (2022)

B-3

内殻電子励起による界面固相反応の制御佐藤 和久
顕微鏡 57 58-59 (2022)

B-4

原爆被爆の誤解中島 裕夫

FBNews 544 1-5 (2022)

B-5

改正RI規制法で要求される放射線測定器の点検と校正について
鈴木 智和

FBNews 555 1-5 (2023)

III
Achievements
37

IRS ANNUAL REPORT

2022

Presentations
P-1

P-2

高発がんメダカrev3l変異体のがんゲノム解析

藤原 智子, 藤川 芳宏, カネラ アンドレス, 庄司 竜麻, 孫 菲, 瀬々 潤, 藤堂 剛
日本放射線影響学会第65回大会, 2022年9月

Read with Exerts

Takashi Kamiya
13th Congress of WOFNMB, 2022年9月

P-3

Evaluation of standardized uptake values and washout rates ofrepresentative abdomen organs in indium-111 pentetreotide single-photon emission
tomography/ computed tomography: comparison to renal function
Takashi Kamiya, Tadashi Watabe, Rie Ikeda, Reina Hagura, Hidetaka Sasaki, Sadahiro Naka, Koichi Fujino,
Keiko Matsunaga, Eku Shimosegawa, Mitsuaki Tatsumi and Hiroki Kato
SNMMI 2022 Annual Meeting, 2022年6月

P-4

転写因子Tfs1/TFIISはDNA-RNAハイブリッド形成を促進することでセントロメアでの染色体異常を誘発する
Xu Ran, Tang Crystal, 中川 拓郎
日本分子生物学会（第45回）, 2022年11月

P-5

P-6

P-7

P-8

Mongia Piyusha, Ziyi Pan, 沖慶 太郎, 豊福 直子, 中川 拓郎
日本分子生物学会（第45回）, 2022年11月

ヘテロクロマチン構造による転写制御を介した染色体異常の抑制
Xu Ran, Tang Crystal, 中川 拓郎
日本生化学大会（第95回）2022年11月

セントロメア領域での転写再開は R-loop を介して染色体異常を誘発する

Xu Ran, Tan Crystal, 中川 拓郎
日本遺伝学会（第94回大会）, 2022年9月

マウス消化管におけるセシウム137 内部被ばくの突然変異と発がんへの影響

III

大野 みずき, 石原 弘, 中島 裕夫
日本放射線影響学会 第65回大会, 2022年9月

Achievements

P-9

分裂酵母Srr1とSkb1はセントロメア領域のDNA反復配列を介した染色体異常を促進する

福島第一原子力発電所事故後の旧警戒区域における放射線被ばくが野生ニホンザルの肝臓と膀胱の酸化ストレス状態に及ぼす影響石川 諒椰, 鈴木 正敏, 木野 康志, 遠藤 暁, 中島 裕夫, 岡 壽崇, 高橋 温, 清水 良央, 鈴木 敏彦, 篠田 壽, 山下 琢磨, 奥津 賢一,
礒部 理央, 福本 学, 千田 浩一
日本放射線影響学会 第65回大会, 2022年9月

P-10

野生ニホンザルと動物実験マウスの肝臓を用いた
低線量・低線量率放射線被ばくによる酸化ストレスマーカーMDA 濃度変化の検討

鈴木 正敏, 石川 諒椰, 中島 裕夫, 木野 康志, 遠藤 暁, 礒部 理央, 千田 浩一, 福本 学
日本放射線影響学会 第65回大会, 2022年9月

P-11

P-12

137Cs の低線量内部被曝による抗腫瘍性免疫サイトカインの増加

中島 裕夫, 大野 みずき, 石原 弘, 宇野 賀津子
日本放射線影響学会 第65回大会, 2022年9月

低線量放射線で誘導されたマウス白血球におけるγ-H2ax 陽性細胞とDNA損傷応答RNAの同時高感度定量法
田中 泉, 石原 弘, 中島 裕夫, 大野 みずき, 田中 美香, 横地 和, 上原 章寛, 武田 志乃
日本放射線影響学会 第65回大会, 2022年9月

P-13

Non-destructive and position selective elemental analysis method using negative muon
Kazuhiko Ninomiya
43rd International Symposium on Archaeometry (ISA 2020/2022), 2022年5月

P-14

素粒子ミュオンによる鋼鉄中炭素濃度の非破壊深度分布測定

P-15

機能性アルカンチオール自己組織化単分子膜における官能基の反応とイオン化

二宮 和彦
日本鉄鋼協会 第185回春季講演大会, 2023年3月

棟安 陸, 室山 瑞穂, 小早川 なの, 津田 泰孝, 坂本 徹哉, 渡部 誠也, 山田 剛司, 赤井 恵, 岡田 美智雄, 吉越 章隆, 加藤 浩之
第16回分子科学討論会, 2022年9月

IRS ANNUAL REPORT

2022

38

P-16

グラファイト表面上の芳香族炭化水素超薄膜のナノスケール構造と電子特性

P-17Comparison of Astatine and Iodine adsorption on Au(111) surface

村瀬 菜摘, 野島 周人, 林田 紘輝, 加藤 浩之, 岡田 美智雄, 赤井 恵, 金 大貴, 渋田 昌弘, 山田 剛司
第16回分子科学討論会, 2022年9月

Jeffrey Tanudji, Hideaki Kasai, Michio Okada, Tetsuo Ogawa, Susan Me_ez Aspera, and Hiroshi Nakanishi
The 22nd International Vacuum Congress IVC-22, 2022年9月

P-18

Adsorption of Iodine on Au(111) surface: coverage effectJeffrey Tanudji, Hideaki Kasai, Michio Okada, Tetsuo Ogawa, Susan Me_ez Aspera, and Hiroshi Nakanishi
The 22nd International Vacuum Congress IVC-22, 2022年9月

P-19

Manufacturing of [211At]NaAt for the first-in-human clinical trial oftargeted alpha therapy for differentiated thyroid cancer at Osaka University Hospital
Kazuhiro Ooe, Sadahiro Naka, Yoshifumi Shirakami, Eku Shimosegawa, Hiroki Kato, Mitsuaki Tatsumi,
Hiromitsu Haba, Atsushi Toyoshima and Tadashi Watabe
Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting, 2022年7月

P-20

分化型甲状腺がんのアルファ線核医学治療第I相試験のためのアスタチン化ナトリウムの製造

大江 一弘, 渡部 直史, 白神 宜史, 南部 明弘, 羽場 宏光, 畑澤 順
第62回日本核医学会学術総会, 2022年9月

P-21

核医学利用に向けたCe-141の加速器製造と分離精製の検討

大江 一弘, 渡部 直史, 白神 宜史, 南部 明弘, 羽場 宏光, 畑澤 順
日本放射化学会第66回討論会(2022), 2022年9月

P-22

内殻電子励起による界面固相反応の制御

P-23

超温度場格子欠陥アナリシス：先端分析材料科学

P-24

Time-resolved observation of photoinduced phase transition of pentoxide by
ultrafast electron microscopy

III

佐藤 和久
日本顕微鏡学会第65回シンポジウム, 2022年11月

佐藤 和久
超温度場材料創成学 公開シンポジウム, 2022年10月

Achievements

S. Hatanaka, T. Tsuchiya, S. Ichikawa, J. Yamasaki, K. Sato
14th International Symposium on Atomic Level Characterizations for New Materials and Devices’22 (ALC'22), 2022年10月

P-25

LBPF法により作製したSUS316L鋼の透過電子顕微鏡による微細組織解析

P-26

電子励起によるPt/SiOx界面での固相反応

P-27

パルス電子顕微鏡によるTi3O5の光誘起相転移の時間分解観察

P-28

超高速電子顕微鏡を用いたTi3O5の光誘起相転移その場観察

P-29

TaSe2の長周期構造と構造欠陥に及ぼすTi添加効果

P-30

P-31

39

佐藤 和久, 高木 空, 市川 聡, 石本 卓也, 中野 貴由
日本金属学会2022年秋期(第177回)講演大会, 2022年9月

佐藤 和久
日本物理学会2022年秋期大会, 2022年9月

畑中 修平, 土屋 汰朗, 市川 修平, 山﨑 順, 佐藤 和久
日本物理学会2022年秋期大会, 2022年9月

畑中 修平, 土屋 汰朗, 市川 修平, 佐藤 和久, 山﨑 順
日本顕微鏡学会第78回学術講演会, 2022年5月

佐藤 和久, 松下 隼也
日本顕微鏡学会第78回学術講演会, 2022年5月

LPBF法により作製したAl合金板材の摩擦攪拌接合部の組織と力学特性

真鍋 光喜, 石本 卓也, 佐藤 和久, 恵久春 佑寿夫, 森貞 好昭, 藤井 英俊, 中野 貴由
日本金属学会2022年春期(第170回)講演大会, 2022年3月

電子照射によるPt/SiOx界面でのα-Pt2Si形成

佐藤 和久, 森 博太郎
日本金属学会2022年春期(第170回)講演大会, 2022年3月

IRS ANNUAL REPORT

2022

P-32

Synthesis and Preclinical Evaluation of 225Ac-PSMA-617 forTargeted Alpha Therapy in Mice with Prostate Cancer

白神 宜史, 渡部 直史, 兼田 加珠子, 角永 悠一郎, 大江 一弘, 豊嶋 厚史, 永田 光知郎, 吉村 崇, 塚田 和明,
白崎 謙次, 菊永 英寿, J Cardinale, F Giesel, 神野 直哉, 深瀬 浩一
IMR-Oarai & Oarai-Alpha Workshop, 2022年9月

P-33

211

P-34

難治性甲状腺がんに対するアスタチンを用いた医師主導治験

At標識PSMA誘導体による前立腺がんα線核医学治療

白神 宜史, 角永 悠一郞, 渡部 直史, 兼田 加珠子, 神野 直哉, 大江 一弘, 羽場 宏光, 豊嶋 厚史, 深瀬 浩一
第5回日本核医学会分科会 放射性薬品科学研究会 第21回放射性医薬品・画像診断薬研究, 2022年9月

渡部 直史, 仲 定宏, 大江 一弘, 豊嶋 厚史, 王 洋, 羽場 宏光, 白神 宜史
第59回アイソトープ・放射線研究発表会 2022年7月

P-35

がんの創薬研究：PET画像診断からα線核医学治療へ

P-36

Targeted alpha therapy using astatine (211At)-labeled PSMA5:
a preclinical evaluation as a new novel compound

白神 宜史
ギルソン社ピペットマン生誕50周年記念 研究フォーラム, 2022年6月

Tadashi Watabe, Kazuo Kaneda, Yoshifumi Shirakami, Yuichiro Kadonaga, Kazuhiro Ooe, Yang Wang,
Hiromitsu Haba, Atsushi Toyoshima, Koichi Fukase
Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting, 2022年7月

P-37

Synthesis and preclinical evaluation of PSMA ligands labeled with astatine-211
Yoshifumi Shirakami, Tadashi Watabe, Yuichiro Kadonaga, Kazuo Kaneda, Kazuhiro Ooe, Yang Wang,
Hiromitsu Haba, Atsushi Toyoshima, Koichi Fukase
Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting, 2022年7月

P-38

At-211-labeled L-tyrosine derivatives via neopentyl scaffold for targeted α-therapy
Yuta Kaizuka, Hiroyuki Suzuki, Tadashi Watabe, Yoshifumi Shirakami, Kazuhiro Ooe, Takahiro Teramoto,Atsushi Toyoshima, Tomoya Uehara
Int Symp Radiopharm Sci 2022, 2022年5月

P-39

III

線維芽細胞活性化タンパク質を標的としたセラノスティクス

P-40

ヒヤリハット事例の収集に関するアンケートのお願い

P-41

教育訓練教材作成のためのヒヤリハット情報提供のお願い

P-42

P-43

Achievements

Tadashi Watabe, Yuwei Liu, Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Sadahiro Naka, Kazuhiro Ooe,
Atsushi Toyoshima, Kojiro Nagata, Frederik Giesel
第16回日本分子イメージング学会総会・学術集会, 2022年5月
鈴木 智和
第18回日本放射線安全管理学会6月シンポジウム, 2022年6月

鈴木 智和, 桧垣 正吾, 髙橋 賢臣
令和4年度日本アイソトープ協会放射線安全取扱部会年次大会, 2022年10月

短寿命RI供給プラットフォームに販売業の届出が不要である主張

鈴木 智和, 渡部 浩司, 千賀 信之
第4回日本保健物理学会・日本放射線安全管理学会合同大会, 2022年11月

教育訓練教材作成のためのヒヤリハット情報収集プロジェクト

鈴木 智和, 桧垣 正吾, 髙橋 賢臣
第4回日本保健物理学会・日本放射線安全管理学会合同大会, 2022年11月

P-44

ヒヤリハット事例を活用した業務の改善と安全文化醸成活動

P-45

ヒヤリハット事例を活用した業務の改善と安全文化醸成活動

P-46

Experimental Study at RCNP for the PANDORA Project

鈴木 智和
公益財団法人原子力安全技術センター令和4年度放射線安全管理講習会, 2022年12月

鈴木 智和
公益財団法人原子力安全技術センター令和4年度医療機関のための放射線安全管理講習会, 2023年1月

Atsushi Tamii
8th Workshop on Level Density and Gamma Strength Function, 2022年5月

IRS ANNUAL REPORT

2022

40

P-47

Electric dipole excitation of nuclei studied by proton scattering

Atsushi Tamii
YKIS2022b:Mean-field and Cluster Dynamics in Nuclear Systems 2022 (MCD2022), 2022年5月

P-48

P-49

エマルションを利用したレーザープラズマからのガンマ線計測技術の開発

民井 淳, 岩崎 遼太, 森 浩睦, 小林 信之, 大田 晋輔, 井上 梓, 須藤 高志, 新名 嶺偉, 川畑 貴裕, 古野 達也, 足立 智,辻 聖也, 本多 祐也, 宮本 憲伸, 新倉 潤, 仲澤 和馬, 六條 宏紀, 西内 満美子, 榊 泰直
OPTO2022 Symposium on Photon and Beam Science, 2022年6月

Experimental Study on Photo-nuclear Reactions by Proton Scattering
Atsushi Tamii
光核スクール, 2022年7月

P-50

PANDORA project: photo-nuclear reactions and decay of nuclei below A=56
Atsushi Tamii
UKAKUREN-RCNP Conference on AstroNuclear Physics (ANP2022), 宇宙核物理の展開, 2022年7月

P-51

光核励起、巨大共鳴、崩壊

P-52

Experimental approach to Ktau using CAT-M active target andGrand Raiden spectrometer

民井 淳
Nuclear Reaction Theories 2022, 2022年7月

Shinsuke OTA
Advances On Giant Nuclear Monopole Excitations And Applications To Multi-Messenger Astrophysics, 2022年7月

P-53

原子核の双極子応答
Atsushi Tamii
RCNP研究会「低エネルギー核物理と高エネルギー天文学で読み解く中性子星」, 2022年8月

III
Achievements

P-54

高速イオン照射によるメタノール液滴表面における 負解離イオン反応過程

P-55

Experimental Plan on the Measurement of Electric Dipole Excitation and Decay of
Nuclei below a mass of 56 using a proton beam at RCNP for the PANDORA Project

水並 優樹, 間嶋 拓也, 寺本 高啓, 土田 秀次, 斉藤 学
第15回分子科学討論会, 2021年9月

Atsushi Tamii
International Nuclear Physics Conference (INPC2022), 2022年9月

P-56

新実験手法による光核反応の定量化

P-57Electric Dipole Response of Nuclei Studied by Proton Scattering

民井 淳
高エネ原子核宇宙研究会, 2022年9月

Atsushi Tamii
ECT* Workshop on Giant and Soft Modes of Excitation in NuclearStructure and Astrophysics, 2022年10月

P-58

An approach to the surface term of nuclear incompressibility forthe precise determination of the incompressibility of nuclear matter
Fumitaka Endo
JSPS/NRF/NSFC A3 Foresight Program Nuclear Physics in the 21st Century, 2022年11月

41

P-59

軟X線顕微鏡による糸状性シアノバクテリアの元素分布の定量的可視化

P-60

紫外サブ10fsパルスレーザーを用いたテトラセン分子の励起状態ダイナミクスの解明

P-61

アスタチン化合物の表面増強ラマン分光

P-62

ヘリウムナノ液滴に捕捉された分子の量子波束の観測:運動量画像観測装置の開発

寺本 高啓
第95回日本生化学会大会, 2022年11月

寺本 高啓, Jun Liu,Juan Du, 小林 孝嘉
第16回分子科学討論会, 2022年9月

寺本 高啓, 中川 創太, 加納 英明, WANG Yang, 羽場 宏光, 豊嶋 厚史
日本放射化学会第66回討論会,2022年9月

安達 大貴, 大澤 萌香, 奥村 拓馬, 松本 淳, 寺本 高啓, 久間 晋, 歸家 令果, 東 俊行
原子衝突学会第47回年会, 2022年9月

IRS ANNUAL REPORT

2022

P-63

Revealing the ultrafast dynamics in tetracene molecules with sub-10fs UV pulse laser
TERAMOTO Takahiro, LIU Jun, DU Juan, KOBAYASHI Takayoshi
37th Symposium on Chemical Kinetics and Dynamics, 2022年6月

P-64

Toward the investigation of wave packet dynamics in He nanodroplets byvelocity map imaging
KUMA Susumu, TERAMOTO Takahiro, AZUMA Toshiyuki
37th Symposium on Chemical Kinetics and Dynamics, 2022年6月

P-65

核医学セラノスティクスとは?

P-66

がん関連線維芽細胞を標的としたFAPI-PETはFDG-PETを超えるか?

P-67

がん関連線維芽細胞を標的としたセラノスティクス：FAPI-PETと今後の展望

P-68

Theranostics targeting FAP

渡部 直史
第16回令和私塾, 2022年12月

渡部 直史
第924回放射線診療研究会, 2022年12月

渡部 直史
第101回東海核医学セミナー, 2022年12月

Tadashi Watabe
Annual meeting of Society of Nuclear Medicine, 2022年11月

P-69

Current status and future perspective in Japan
Tadashi Watabe
ICPO Theranostics FAP Summit, 2022年11月

P-70

セラノスティクスに関する国内外の最新の動向

P-71

Astatine (211At) as a novel targeted alpha therapy for thyroid cancer and beyond

渡部 直史
第27回東海腫瘍核医学研究会, 2022年10月

III

P-72

Achievements

Tadashi Watabe
Seminar in KIRAMS (Virtual), 2022年10月

Evaluation of LAT1 expression in patients with lung cancers and mediastinal t
umors: [18F]FBPA PET study with immuno-histopathological comparison

Tadashi Watabe, Naoko Ose, Sadahiro Naka, Eriko Fukui, Takashi Kanou, Soichiro Funaki, Hidetaka Sasaki,
Takashi Kamiya, Kenta Kurimoto, Eku Shimosegawa, Hiroki Kato, Ryuichi Ohgaki, Yoshikatsu Kanai, Yasushi Shintani
EANM2022, 2022年10月

P-73

アスタチン標識PSMA5を用いた新規標的α線治療の評価：前立腺癌モデルでの検討
Tadashi Watabe, Kazuko Kaneda, Atsushi Toyoshima, Koichi Fukase
第81回日本癌学会学術総会, 2022年9月

P-74

標的アルファ線治療の臨床応用の現状と今後の展望

P-75

89

渡部 直史
第62回日本核医学会学術総会, 2022年9月

Zr標識Glypican-1抗体を用いたImmuno-PET：膵癌における セラノスティクスに向けて
渡部 直史
第62回日本核医学会学術総会, 2022年9月

P-76

211

P-77

Targeted Alpha Therapy using Astatine (211At) against Differentiated Thyroid Cancer

P-78

PET imaging and therapy targeting PSMA: current status and perspective in Japan

At標識PSMA-5を用いた標的アルファ線治療：非臨床での評価

渡部 直史
第62回日本核医学会学術総会, 2022年9月

渡部 直史
世界核医学会2022(WFNM2022), 2022年9月

渡部 直史
世界核医学会2022(WFNM2022), 2022年9月

IRS ANNUAL REPORT

2022

42

P-79

PSMA-PETの驚異的な検出能と臨床的有用性

P-80

セラノスティクスに関する国内外の最新の動向

P-81

RAI不応性甲状腺癌に対する アスタチンを用いたα線治療

P-82

Immuno-PET using 89Zr-labeled Glypican-1 antibody: a novel theranostic probe forthe antibody-drug conjugate treatment in pancreatic cancer

渡部 直史
PETサマーセミナー2022, 2022年7月

渡部 直史
第30回宮城県核医学研究会, 2022年7月

渡部 直史
第34回日本内分泌外科学会総会, 2022年6月

Tadashi Watabe, Sadahiro Naka, Satoshi Serada, Eku Shimosegawa, Tetsuji Naka
米国核医学会2022 (SNMMI2022), 2022年6月

P-83

前立腺癌におけるPSMA-PETの驚くべき検出力と臨床的有用性

P-84

Laser isotope separation to study for the neutrino-less double beta decay of 48Ca

渡部 直史
第81回日本医学放射線学会総会, 2022年4月

I. Ogawa
28th International Nuclear Physics Conference (INPC2022), 2022年9月

P-85

Status of the search for 48Ca double beta decay with CANDLES
Yuto MinamiInternational Conference on High Energy Physics (ICHEP2022), 2022年6月

P-86

Laser isotope separation of calcium

Shigeki Tokita
Unraveling the History of the Universe and Matter Evolution with Underground Physics(UGAP2022), 2022年6月

III

P-87

Energy Resolution Improvement for CaF2 Scitillating Bolometerby Machine Learning Analysis

Achievements

Unraveling the History of the Universe and Matter Evolution with Underground Physics(UGAP2022), 2022年6月

P-88

Data analysis for reduction of 208Tl background events in CANDLES system

P-89

Improvement of pulse shape discrimination analysis forbackground reduction in CANDLES

Unraveling the History of the Universe and Matter Evolution with Underground Physics(UGAP2022), 2022年6月

Unraveling the History of the Universe and Matter Evolution with Underground Physics(UGAP2022), 2022年6月

P-90

二重ベータ崩壊と同位体濃縮

P-91

The status of laser isotope separation (LIS) of48
Ca for the study of neutrino-less double beta decay

小川 泉
第2回研究用原子炉を用いた原子核素粒子物理学, 2022年5月

Anawat Rittirong
第20回 同位体科学研究会, 2023年3月

P-92

Synthesis and Properties of Pyrazine or 4,4'-Bipyridine - Bridged
Octahedral Hexanuclear Rhenium Cluster Dimer
Takashi YOSHIMURA, Motohiro NAKANO, Kojiro NAGATA
錯体化学会第72回討論会, 2022年9月.

P-93

Stability of a Series of the Rare-earth Complexes with
Nonadentate Ligands Having Three Picolinic Acid Arms
Kojiro Nagata, Yota Ishida, Tatsuo Yajima, Takashi Yoshimura
錯体化学会第72回討論会, 2022年9月

43

IRS ANNUAL REPORT

2022

P-94

アゾール配位子をもつニトリドレニウム(V)錯体の合成と配位子のプロトン付加/脱離による発光挙動 の変化

宮本 颯大, 永田 光知郎, 吉村 崇
錯体化学会第72回討論会, 2022年9月

P-95

P-96

電解酸化反応を用いたチロシン上ヨウ素 - アスタチン置換反応

中川 創太, 角永 悠一郎, 大江 一弘, 寺本 高啓, 床井 健運, 永田 光知郎, 吉村 崇, 羽場 宏光, 王 洋, 笠松 良崇,
豊嶋 厚史, 深瀬 浩一, 篠原 厚
日本放射化学会第66回討論会(2022), 2022年9月

In vitro で形成させたヒドロキシアパタイトに吸着した Ra-226 の局所構造解析

永田 光知郎, 山口 瑛子, 小林 徹, 下条 晃司郎, 横山 啓一, 谷田 肇, 矢板 毅, 高橋 嘉夫, 吉村 崇
日本放射化学会第66回討論会(2022), 2022年9月

Co のミュオン原子核捕獲反応生成物の測定

P-97

59

P-98

燃料デブリ取り出し作業での生成を模擬したウラン微粒子の分析

P-99

137
90
福島第一原発事故に由来する Csと Srの深度分布と移流拡散モデルによる解析

P-100

浅利 駿介, Chiu I-Huan, 新倉 潤, 佐藤 朗, Amato Alex, Biswas Sayani, Gerchow Lars, 二宮 和彦, 吉村 崇
日本放射化学会第66回討論会(2022), 2022年9月

豊嶋 厚史, 高宮 幸一, 永田 光知郎, 古谷 浩志, 床井 健運, 寺本 高啓, 稲垣 誠, 河井 洋輔, 吉村 崇, 豊田 岐聡, 篠原 厚
日本放射化学会第66回討論会(2022), 2022年9月

山本 康平, 吉村 崇, 二宮 和彦
日本放射化学会第66回討論会(2022), 2022年9月

分子レベルの情報に基づいたラジウムの環境挙動解明山口 瑛子, 永田 光知郎, 小林 恵太, 田中 万也, 小林 徹, 谷田 肇, 矢板 毅, 吉村 崇, 奥村 雅彦, 高橋 嘉夫
日本放射化学会第66回討論会(2022), 2022年9月

III
Achievements

IRS ANNUAL REPORT

2022

44

Awards
A-1

Poster Award (Second Place) - Oncology, Basic, and Translational

Tadashi Watabe, Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Yuichiro Kadonaga, Kazuhiro Ooe,
Yang Wang, Hiromitsu Haba, Atsushi Toyoshima, Jens Cardinale, Frederik L. Giesel, Koichi Fukase
米国核医学会(SNMMI), 2022年6月

A-2

2022 ERF SNMMI-TS Professional Development Grant Award for
the SNMMI Annual Meeting

Takashi Kamiya, Tadashi Watabe, Rie Ikeda, Reina Hagura, Hidetaka Sasaki, Sadahiro Naka, Koichi Fujino,
Keiko Matsunaga, Eku Shimosegawa, Mitsuaki Tatsumi and Hiroki Kato
SNMMI 2022 AnnualMeeting, 2022年6月

A-3

久田賞（Annals of Nuclear Medicine論文賞）銅賞

A-4

日本放射線安全管理学会 令和3年度技術賞

渡部 直史
日本核医学会, 2022年9月

Kazuko Kaneda-Nakashima, Zijian Zhang, Kojiro Nagata, Kenji Shirasaki, Hidetoshi, Kikunaga,
Tomoo Yamamura, Kazuhiro Ooe, Tadashi Watabe, Atsushi, Toyoshima, Takashi Yoshimura, Atsushi Shinohara
一般社団法人日本放射線安全管理学会, 2022年9月

A-5

最優秀ポスター賞

鈴木 智和, 桧垣 正吾, 髙橋 賢臣
公益社団法人日本アイソトープ協会令和4年度安全取扱部会年次大会, 2022年10月

Social and Academic Contributions

III
Achievements

S-1

オートファジーの発見、そしてその発展
野田 健司
西宮市

S-2

直弟子からみたノーベル賞の大隅良典博士
野田 健司
かわさき市民アカデミー

S-3

厚生労働科学研究（細野班）研究協力者
渡部 直史
厚生労働省

S-4

IAEA CUIJ コンソーシアム事務局
渡部 直史
国際原子力機関S-5

大阪府立生野高等学校出張講義「宇宙は明るく光っているのか？」
吉田 斉
出張講義

S-6

医師主導治験（難治性甲状腺がんに対するアスタチン治験）渡部 直史
治験責任医師

45

IRS ANNUAL REPORT

2022

Patents
I-1

放射標識されたチロシン誘導体およびその用途

兼田 加珠子, 白神 宜史, 角永 悠一郎, 豊嶋 厚史, 深瀬 浩一, 長田 宏
特願2022-150608

I-2

甲状腺がんの核医学治療薬
渡部 直史, 白神 宜史
特願2022-202483

I-3

電解酸化反応による放射標識アリール化合物の製造方法

深瀬 浩一, 豊嶋 厚史, 篠原 厚, 白神 宜史, 兼田 加珠子, 下山 敦史, 角永 悠一郎
特願2022-035169

I-4

放射標識されたFAPα親和性化合物およびその用途

白神 宜史, 角永 悠一郎, 兼田 加珠子, 渡部 直史, 深瀬 浩一, 下山 敦史, 麻生 彩佳, 吉矢 拓
特願2022-26194

III
Achievements

IRS ANNUAL REPORT

2022

46

Fund for Preparation of New Education and Research Projects
新規教育研究プロジェクト準備経費
現在、放射線科学基盤機構では、放射線の生物学的影響、福島関連研究、大規模 RI 製造法など、アルファ線

核医学治療に続く新たな教育研究プロジェクトの立ち上げに取り組んでいる。これらを遂行するためには、理学研究科や医学系研究科の部局単位や大阪大学内に留まらない分野横断的な意見の交流が重要である。特にプロジェクトの計画段階で、各分野の専門家の意見を集約、精査することでプロジェクトを取り巻く環境を把握し、科学的かつ社会的に有意義な計画の立案が必要となる。そのため、本機構では、専任教員ならびに兼任教員が新たな教育研究プロジェクトの立上げを行うための準備活動を積極的に支援しており、2019 年度から計画立案者に対する支援を行うために「新規教育研究プロジェクト準備経費」を策定し、公募を行っている。2022 年度

は以下の 4 件の課題を採択し、支援を行なった。

• 高度ミューオン X 線分析による文理協力型新学術創出プロジェクト• 量子ビーム治療における照射領域可視化システム構築の研究開発準備• FAP（線維芽細胞活性化タンパク質）を標的とした新たな臨床研究プロジェクトの立ち上げに向けて• 固体標的への超高強度レーザー照射による放射ガンマ線の計測技術の開発
本年度も大阪大学の部局間に限らず、理化学研究所、近畿大学、京都橘大学、量子科学技術研究開発機構、
富山高等専門学校、福井県立病院、岐阜大学、東京大学と、研究所や病院からも技術者が参画しプロジェクトが推進された。
本取り組みは、放射線科学基盤機構の発展に留まらず、放射線科学関連分野の活性化に資する重要な活動の一つとして位置付け、今後も継続的な支援を行う予定である。次ページ以降に、採択された 4 件の課題の活動
成果報告を載せる。

III
Achievements
47

IRS ANNUAL REPORT

2022

Fund for Preparation of New Education and Research Projects

高度ミューオン X 線分析による文理協力型新学術創出プロジェクト
代表者
参画研究者

佐藤 朗（助教）

1

二宮 和彦（准教授） , 寺田 健太郎（教授） , 中野 貴志（教授） ,3
45
友野 大（特任助教（常勤）） , 上田 直弥（助教） , 髙橋 京子（招へい教授） ,678
新倉 潤（協力研究員） , 高浦 佳代子（講師） , 南 健太郎（准教授）213

		1 大阪大学 大学院理学研究科
		2 大阪大学 放射線科学基盤機構
		3 大阪大学 核物理研究センター
		 4 大阪大学 埋蔵文化財調査室 / 大学院文学研究科
		 5 大阪大学 総合学術博物館 / 適塾記念センター
		 6 理化学研究所 仁科加速器科学研究センター
		 7 近畿大学 薬学部
		 8 京都橘大学 文学部 歴史遺産学科
配分額300,000 円

実績額

300,000 円

本学は、連続状ミューオンビーム施設「核物理研究センター MuSIC」を有し、研究代表者の佐藤、二宮を中心に連続状ミューオンを使った新しい学術領域の開拓を牽引する位置にあります。特にミューオン X 線の分光測定については、本学の連続状ミューオンにより高精度かつ詳細な研究が実現可能で、様々な分野から発展が期待されています。非破壊かつ非接触で物質内部の元素組成や同位体比を分析出来るこの手法は、地球宇宙科
学や考古学 ･ 文化財科学など破壊を伴う分析が許可されないような超貴重資料を扱う学術分野にも化学分析による研究手法を提供し、従来実現不可能であった客観的科学データによる新しい研究の創出へつながると注目を集めています。本プロジェクトでは、このような本学のミューオン科学の優位性を活かして、学術のみならず産業界も含めた文理協力の元に、大阪大学がリーダーシップを取って高度ミューオン X 線分析を推し進める体制を構築して、新しい学術研究の創成を目指します。

III
Achievements

本年度は、国内外ミューオン施設との連携体制の構築、ミューオン X 線分析国際会議の開催、国内におけるミューオン X 線分析の啓蒙と組織作りなどを進めました。

茨城県にあるパルスミューオン施設 J-PARC-MUSE やスイスの連続ミューオン施設 PSI において、ミューオンを利用した元素分析法の基礎研究を実施し、特に元素の化学状態分析と同位体分析法の開発について成果がありました。小惑星探査機「はやぶさ 2」がリュウグウから持ち帰った地球外サンプルに対するミューオン元

素分析を 2021 年度に J-PARC-MUSE で実施しましたが、そのデータ解析が完了し、結果を他の初期分析結果と共に科学雑誌 Science 上で発表しました。さらに、ミューオン位置測定装置と X 線検出器を組み合わせた

ミューオン X 線分析による 3 次元元素マッピング装置の開発を進めました。開発した装置をスイス PSI のミュー

オンビームラインに設置し、サンプル資料や隕石の 3 次元元素分布測定を実施しました。スイス PSI では、博物

資料、産業試料など様々なサンプルのミューオン元素分析を、我々阪大を中心としたグループとスイスグループ
が協力して進めています。この連携が発展し、阪大 -KEK とスイス PSI グループが協力して応募した国際共同研究プログラム（JRPs）が採択され、2023 年よりリチウムイオン電池や全固体電池などを対象とした高度ミューオン元素分析法を共同開発することとなりました。また、2023年3月には世界初のミューオン X 線分析国際ワー

クショップを企画 ･ 開催し、国際的な研究協力体制の構築を進めました。

リュウグウサンプル初期分析の成果はプレスリリースを行い、マスコミでも大きく取り上げられました。この分析結果やミューオン元素分析の応用などについて、学会やセミナーでの専門家向けの講演を行っただけでな
く、様々な形で一般向けのアウトリーチ活動を行い、ミューオン科学の啓蒙を進めました。

IRS ANNUAL REPORT

2022

48

Fund for Preparation of New Education and Research Projects

量子ビーム治療における照射領域可視化システム構築の研究開発準備
代表者
参画研究者

西尾 禎治（教授）1

坂田 洞察（准教授） , 稲庭 拓（グループリーダー） , 増田 孝充（研究員） ,1

阿蘇 司（教授） , 松下 慶一郎（主査）
3

2

2

4

1 大阪大学 大学院医学系研究科 保健学専攻
2 量子科学技術研究開発機構 量子医学 医療部門 放射線医学総合研究所 物理工学部
3 富山高等専門学校 電子情報工学科
4 福井県立病院 陽子線がん治療センター
配分額

300,000 円

実績額

300,000 円

本研究では、粒子線を利用した量子ビーム治療における照射領域の観える化を目指したテーマにおいて、体内照射領域可視化画像を高品質で取得するシステムの構築を行うことである。患者体内の照射領域内で僅かに起こる原子核破砕反応より生成されるポジトロン放出核を情報因子とすることで体内の量子ビーム照射領域の可視化を行う。

2022 年度の研究では、研究グループが開発した照射ターゲット中での生成ポジトロン放出核の強度分布（Activity 分布）を計測することが可能な Beam ON-LINE PET system（BOLPs）を利用し、名古屋陽子線治療センターで供給可能な治療用エネルギーの陽子線を利用した実験を実施した。人体構成要素である炭素、酸素、カルシウムを含むゼラチン質の水、ポリエチレン、ウレタン、酸化カルシウムの照射ターゲットへの照射実験を行い、BOLPs による計測データから、陽子線照射による炭素、酸素、カルシウム核からの陽電子放出

核生成反応率の相関及び反応断面積の導出を実施した。また、モンテカルロ・シミュレーションコードである

PHITS を利用した BOLPs の陽子線照射実験場の数値シミュレーションを行った。実験データ及び解析より得IIIられた成果の一つとして、陽子線治療において、人体中に含まれる炭素核とがん治療用の入射陽子の飛程近傍

Achievementsでの反応が顕著となる、12C(p,n)12N 反応による照射ターゲット中での 12N の生成量分布の実験データを取得できた点である。この反応により生成される 12N は、陽子線治療における可視化に伴う体内飛程推定に活用できるのではとの報告があったが、この 12N の生成量分布を実験的に示したのでは世界初である。現在、専門の国際雑誌への投稿準備を進めているところである。また、2022 年 10 月より、本研究を含んだテーマで大阪大学と住友重機械工業との共同研究を開始することができた。

今後は、2023 年度から開始する科研費基盤 A を活用するなどして、陽子線を中心とした研究を遂行予定で

ある。

49

IRS ANNUAL REPORT

2022

Fund for Preparation of New Education and Research Projects

FAP（線維芽細胞活性化タンパク質）を標的とした新たな臨床研究プロジェクトの立ち上げに向けて
代表者
参画研究者

渡部 直史（助教）1巽 光朗（准教授） , 白神 宜史（特任准教授） , 仲 定弘（薬剤師）234

		1 大阪大学 大学院医学系研究科 核医学
2 大阪大学 医学部附属病院 放射線部
3 大阪大学 放射線科学基盤機構
4 大阪大学 医学部附属病院薬剤部
配分額300,000 円

実績額

300,000 円

がんの浸潤・転移においては、がん細胞自身の性質に加えて、がん細胞と周囲組織（間質）との間で構成される微小環境が重要である。がんの間質は腫瘍全体の大部分を占めており、特にがん関連線維芽細胞（CAF:

cancer associated fibroblast）はがんの増殖・進展に重要な役割を果たしていることがわかっている。CAF には膜タンパクである線維芽細胞活性化タンパク質（fibroblast activation protein：FAP）が発現しており、乳がん・大腸がん・膵がん・卵巣がん・肝細胞がん等の幅広いがん種での発現が確認されている。

今回、研究代表者と分担者の間で、FAPI-PET の実施および対象患者について、打ち合わせを行い、大型研究プロジェクトの応募のための予備的データの取得のために 2022 年 6 月より FAPI-PET 臨床研究を開始した。

本臨床研究のデータを根拠データとして、今後の大型研究プロジェクトの計画を考える上での予備的データにすると共に、根拠データとして、大型研究プロジェクトへの応募を行った。
【 活動内容 】

1) 研究代表者と分担者の間で、FAPI-PET の実施および対象患者について、打ち合わせを行った。

III2) 医学部附属病院 倫理審査委員会の承認を得て、阪大病院 核医学診療科において、患者より同意を取得し、Achievements

FAPI-PET 検査を実施した。

3) 肺癌や乳癌の患者を中心に FAPI-PET 検査を実施し、既存の FDG-PET や CT 検査と比べて、病変への集積程度や検出能について評価を行い、今後の大型研究プロジェクトの計画を考える上での予備的データにすると共に、予算申請を行う上での根拠データとした。

4) 研究代表者と分担者の間で打ち合わせを行い、大型研究プロジェクト（科研費基盤 B、AMED 次世代がん）への応募を行った。

IRS ANNUAL REPORT

2022

50

Fund for Preparation of New Education and Research Projects

固体標的への超高強度レーザー照射による放射ガンマ線の計測技術の開発
代表者
参画研究者

民井 淳（教授）1大田 晋輔（准教授） , 小林 信之（准教授） , 新名 嶺偉（博士前期課程２年） , 仲澤 和馬（招へい教員） ,3
3
4
4
西内 満美子（上席研究員） , 榊 泰直（上席研究員） , 川畑 貴裕（教授） , 古野 達也（助教）56新倉 潤（助教） , 六條 宏紀（特任助教）
1

1

1

2

		1 大阪大学 核物理研究センター
		2 岐阜大学 教育学部
		3 量子科学技術研究開発機構 関西光科学研究所
		 4 大阪大学 大学院理学研究科
		 5 東京大学 大学院理学系研究科
		 6 東京大学 未来材料システム研究所
配分額

300,000 円

実績額0円

レーザープラズマの動的機構を理解するための診断技術開発およびレーザープラズマ内での原子核反応の証
拠を得ることを目的に、これまでに測定されたことがないレーザープラズマからの放出ガンマ線の直接測定を可能にする技術を、原子核乾板（エマルション）を用いることで確立することが目的である。レーザープラズマの診断技術は世界的に活発に研究開発が進められている対象であるが、これまで放出ガンマ線が計測された例はない。また、レーザー照射場中の核反応の検出はレーザー爆縮核融合などごく一部の特殊条件下の例が存在するのみである。ガンマ線計測は、今後拡大が見込まれる超高集光エネルギー下でおきる粒子加速を調べるた
めに重要な診断技術であり、核反応の定量的測定につながる。ガンマ線計測技術の確立は、今後の世界標準の技術を生み出すことになりインパクトが大きい。
本年度は 2021 年度に関西光科学研究所の J-KAREN-P レーザーを用いて行った開発実験のデータ解析を進IIIめる作業を行った。解析は大阪大学大学院に進学予定の学生（岩崎遼太）を中心として行っている。集光強度

Achievements

1021W/cm2 で時間間隔 30fs の高輝度パルスレーザーを厚さ 5 μ m の銀薄膜標的に 1 ショット照射した。45 度に傾けた標的の下流でビーム進行方向から 10 度の方向において、標的から 1m の距離の真空槽外にエマルション検出器を設置した。エマルションは 30 × 40mm2 を 30 枚重ねたスタックに、ビーム照射時のみさらに 2 枚を加えた構成とした。設置位置として、1 枚スタックのエマルションを複数設置した予備実験によって放射線量が測定に適していると判断した位置を用いている。照射後のエマルションを岐阜大学に移送して、現像および顕微鏡による予備解析を行い、その後名古屋大学未来材料システム研究所の自動スキャンニング装置を用いてスキャンニングによりデータ化した。得られたデータの解析により、ガンマ線を起因とする電子・陽電子対生成の飛跡を 4 例確認している。発見された電子・陽電子の飛跡ゆらぎ解析により、検出したガンマ線のエネルギー

を 39,45,46,76MeV と推定している。ガンマ線の入射方向は、測定角度精度程度でおよそ標的方向を向いている。レーザープラズマからの放射ガンマ線の世界初の直接測定の可能性がある。真空槽において生成されたガンマ線である可能性を排除するためのシミュレーション作業を進めている。この成果の一部を、OPTO2020

会議においてポスター（オンライン）発表した。現在投稿論文の作成を進めている。また、2023 年度には観測状況をより明確にするために、エマルションを真空槽内に設置する測定を行う予定で準備作業を進めている。

2022 年度に関西光科学研究所にて実験を行う計画であったが、ビームタイムを実施できなかったため 2023 年度に行う方針とし、実験旅費として使用する予定であった採択予算全額を機構に返却した。

51

IRS ANNUAL REPORT

2022

Division Summary
各部門の年度計画と活動実績の概要
大阪大学放射線科学基盤機構には、3 つの部門と附属ラジオアイソトープ総合センターがあります。3 つの部門は、放射線科学部門、放射線教育部門、放射線管理部門です。これらが役割分担しながら、放射線を用いる全部局と連携し、大阪大学全体の放射線科学を推進しています。この「アニュアルレポート 2022」には、2022 年度の活動実績の概要を部門ごとに載せ、活動実態をオープンにすることで、ご意見を承る資料とすることにしました。日本語での記載ですが、参考になれば幸いです。

放射線科学基盤機構
機構長

富山 憲幸

III
Achievements

IRS ANNUAL REPORT

2022

52

Division Summary

放射線科学部門

活動実績

Division of Science

部門概要
理学研究科、医学研究科、核物理研究センターとの部局間連携によりアルファ線核医学治療法開発プロジェ
クトを推進しています。2022 年 4 月には、アルファフュージョン株式会社と共同研究講座「アスタチン創薬実用化共同研究部門」を設置し、アルファフュージョン社の人的リソースおよび資金の支援を得て、臨床研究、非臨床研究、開発研究を実施しました。また新たに歯学研究科との部局間連携研究を開始しました。

2022 年度の活動報告
1. 難治性甲状腺がんを対象とする 211At-NaAt の医師主導治験

医学部、医学部附属病院と連携して [211At]NaAt を用いた第Ⅰ相医師主導治験を実施しました。大阪大学

医学部附属病院核医学診療科において、治験薬 GMP 基準下でアスタチン化ナトリウム注射液（211At-NaAt）の安定製造を行いました。第Ⅰ相医師主導治験について、5 例目までの治験薬投与ならびに安全性評価を実施しました。

2. 前立腺がんを対象とする 211At-PSMA の非臨床研究

前立腺特異的膜抗原（PSMA）を標的とする前立腺がん治療薬のスクリーニング研究を 2021 年度に続き実施し、開発候補化合物を選択しました。PMDA 対面助言を行い、本化合物の非臨床試験のデータパッケー

ジにつき PMDA の合意が得られました。医学部、医学部附属病院と連携して非臨床研究を開始しました。

III
Achievements

本技術の特許を PCT 出願しました（PCT/JP2022-29283, 出願日：2022 年 7 月 29 日、出願人：大阪大学）。

3. 211At-FAPI に関する研究

がん間質に発現している線維芽細胞活性化たんぱく質 (FAP) を標的とする新規がん治療薬 211At-FAPI の合成を行い、抗腫瘍効果の評価を行いました。その結果、腫瘍の成長抑制が認められました。本技術は 2023
年 2 月 21 日に PCT 出願しました（PCT/JP2023-00610）。

4. 211At- 金ナノ粒子の合成と抗腫瘍効果の評価

At- 金ナノ粒子の腫瘍への直接投与、尾静脈投与、もしくは腹腔内投与によるがん治療について検討しま

211

した。C6 glioma 移植ラットおよび PANC1 移植マウスへの局所投与では、著しい腫瘍増殖抑制効果を示しました。歯学研究科と連携し、舌癌を対象にした研究を開始しました。がんモデルマウスにおいて、211At金ナノ粒子の尾静脈投与によっても、優れた抗腫瘍効果を示すことを確認しました。

5. L 型アミノ酸トランスポーター（LAT1）基質を用いたα線核医学治療研究

腫瘍に選択的に発現する LAT1 を標的とし、211At-AAMT に次ぐ薬剤候補として、集積性・滞留性により優れた LAT1 基質の開発研究を行い、製造・品質・生物試験を実施しました。

At 標識 -L- アルファメチル -O- メチルチロシン (L-211At-AAMT-OMe) について、抗がん剤耐性株（ゲムシ211

タビン耐性膵がん細胞）を用いた細胞を用いた動物モデルにおいて、優れた治療効果を認めました。

特許出願：発明の名称：放射標識されたチロシン誘導体およびその用途（特願 2022-150608、出願日：2022 年

9 月 22 日）

その他、バックアップ化合物について開発を行いました。

53

IRS ANNUAL REPORT2022

6. 211At の電解酸化標識法に関する研究

チロシンなどのハロゲン化フェノール含有化合物に対する、電解酸化による At 標識法について検討しました。
フロー電解装置を用い、N- アセチル -3- ヨードチロシンに 211At を電解標識して 211At 標識化チロシン誘導体を得ました。

7. 211At の光標識法に関する研究

ハロゲン化フェノール含有化合物に対する紫外光による At 標識法について検討しました。

8. 211At 標識抗体に関する研究

At 標識抗体の細胞傷害活性ならびに抗腫瘍活性について検討しました。211At リンカー核移行型の抗体の211創成に成功し、従来のリンカーと比較して DNA 二重鎖切断 (DSB) 活性の向上を確認しました。また、金ナノ粒子を導入した抗体について、DSB 活性ならびに腫瘍集積性を評価しました。211At の部位特異的標識抗体については PCT 出願を実施しました。（PCT/JP2022/035783）

9. 様々な新規モダリティーに関する研究

腫瘍への送達および細胞内在化能が優れた新規モダリティー（中分子・ペプチドなどの様々な化合物群）について、フローサイトメトリーおよびライブセルイメージングによる内在化解析、DSB 活性を行い、複数の新規標的医薬候補を見出しました。

10. 新規ベータ線治療核種 47Sc の研究開発

新規ベータ線治療核種 47Sc について、東北大学電子光理学研究センターで 47Sc の製造と分離精製を実施し、いくつかの標識化合物について標識条件の検討を行いました。

11. その他

令和４年度から核物理研究センターの更新した AVF サイクロトロンを用いて 211At 製造供給を開始しました。

III
Achievements

IRS ANNUAL REPORT

2022

54

Division Summary

放射線教育部門

活動実績

Division of Education

部門概要
本部門では、全学の放射線教育ならびに人材育成を進めています。学部および大学院での部局横断的な放射線教育プログラムの開発を行い、展開していくことにより、大学初年次からの放射線教育を充実させ、様々な分野で活躍できる人材育成を目指しています。また、国際交流を通じて、国際的な放射線教育ならびに人材育成の拠点を構築していきます。

2022 年度の活動報告
以下、本部門が行った 2022 年度の活動について報告をします。

1. 部局を跨がる教育プログラムとして大学院等高度副プログラムを提供しました。当機構が主体となり、核物理研究センター、医学研究科および理学研究科の協力のもと実施している「放射線科学」です。今後、更に多くの部局の協力を得て、分野横断的な教育プログラムへと充実させていく予定で 2023 年度開講のための科目の編成見直しを行い、プログラム名も「共創的放射線教育プログラム（CREPE）」に変更しました。工

学研究科からも科目が提供されています。大学院生用の CREPE は 2023 年度開講予定で採択をされました。

2. 2020 年度に採択された原子力規制人材育成事業「社会との共創による原子力規制人材育成プログラム」

III（2020 年度〜 2024 年度）について、2022 年度分の事業を行いました。本事業では、核物理研究センター、

Achievements

安全衛生管理部ならびに全学教育推進機構の協力を得て、福島県浜通り地区での環境放射線研修会を中心とした共創的放射線教育プログラム（CREPE）を前年度に引き続き開講しました。2022 年度には履修者

は 30 名になり、うち７名が 2023 年 3 月にプログラムを修了しました。修了者の発表状況から鑑みますと、大変優秀な学生が育っている印象です。この CREPE プログラムの広報のため、ホームページ（https://www.rcnp.osaka-u.ac.jp/crepe/）並びにパンフレットを改訂・作成をしました。6 月 11 日に開催された

55

IRS ANNUAL REPORT

2022

「大阪大学共創 DAY@EXPOCITY」にて、CREPE 履修生がポスター展示を行いました。このイベントでは CREPE 履修学生が福島での活動について一般の方に紹介しました。また、CREPE の中心的な科目である福島県浜通り地区環境放射線研修会に放射線教育部門として参画しました。7 月の土曜日を利用して、環境放射線の現地研修を控えた事前講義を 3 日に渡り行い、8 月 21 日〜 26 日（5 泊 6 日）と 9 月 18 〜 23 日（5泊 6 日）の 2 回に分けて、福島県浜通り地区において環境放射線の現地研修を行いました。参加者学生が他大学含めて 123 名に増えました。本研修会の成果は 8 月 29 日と 9 月 26 日に大阪大学豊中キャンパスにおいて開催された研修の最終討論会において学生により発表されました。8 月の研修会では、教育担当の田中理事に視察をいただき、高い評価を得ることができました。

3. 2022 年度も、全学共通教育科目として「【総合】放射線の自然科学、社会学、人文学」を開講しました。
20 名の履修登録があり、そのうち 14 名が合格しました。今回は大学院生の履修も可能とし、1 名が履修しました。また、2022 年度も、原子力規制庁から講師を招き講義を行ってもらい、履修学生に大変好評でした。

4. 学問への扉「身の回りの放射線の科学」を機構として実施しました。履修登録者数は 17 名でした。本プロ
グラムに関して 1 名の大学院生が TA を行いました。

5. 2022 年度は、JST さくらサイエンスプログラム 9 月を福島県浜通り地区環境放射線研修会に合わせて実施しました。

6. 2 月にグローニンゲン大学に CREPE 履修の学部学生 2 名を派遣して国際シンポジウムを開催しました。
（https://www.osaka-u.ac.jp/ja/news/topics/2023/04/03001）

7.「多様な知の協奏による先導的量子ビーム応用卓越大学院プログラム」に、放射線教育部門として参画しました。また、理工情報系オナー大学院プログラムや次世代挑戦的研究者育成プロジェクトにも教育部門としIIIて、運営の面で貢献しました。

Achievements

IRS ANNUAL REPORT

2022

56

Division Summary

放射線管理部門

活動実績

Division of Safety Management

部門概要
本部門では、学内の放射線施設及び核燃料物質使用施設と連携、放射線安全管理に関する事項を総合調整し、全学の放射線管理を総括する業務を行っています。また、緊急時、事故時には、本機構に属する教職員が事態収拾やその際の情報提供に対して応援及び協力することで、学内の放射線施設が一体となってリスク管理を行う体制を構築しています。

2022 年度の活動報告
以下、本部門が行った今年度の活動について報告をします。

1. 放射線取扱主任者の免状取得への援助

放射線取扱主任者の免状取得奨励のために、2022 年度に学内放射線施設の主任者又は主任者の代理者になる予定の者を対象に、第 1 種放射線取扱主任者講習の受講料と旅費の援助を募集し、計 2 名に援助しました。

2. 学内放射線施設自主安全・管理点検活動への協力

原子力研究・安全委員会放射線安全管理部会が行う学内放射線施設自主安全・管理点検活動では、各放射線施設が自己点検を行う年度、及び自己点検に加えて点検委員が各施設を点検する年度を交互におこなっています。2022 年度は、点検委員が各施設を点検する年度でした。各施設が自己点検をした後、10 月に点検委員及III

び各施設の管理担当者による会議 ( 第 1 回 ) を開催し点検内容を確認しました。11 月〜 12 月にかけて点検委員

Achievements

が各施設を訪問し点検を実施しました。各施設の点検結果については、2 月に会議 ( 第 2 回 ) を行い、各施設で情報共有しました。これらの点検の報告については冊子にとりまとめ、年度末に安全衛生管理室を通じて大学
本部及び関係部局、関係者に配付しました。

57

IRS ANNUAL REPORT

2022

Division Summary

活動実績

ラジオアイソトープ総合センター
Radioisotope Research Center

部門概要
ラジオアイソトープ総合センター（RI 総合センター）は、放射線業務従事者への安全教育を行うとともに各種放射線実験設備を整備し、各部局の共同利用に供すること、全学的放射線安全管理とこれに関連した研究を実施することを目的としています。

2022 年度の活動報告
以下、本センターが行った今年度の活動について報告をします。

1. 安全管理・放射線教育訓練に関する業務

学内 13 の非密封放射性同位元素を使用する施設の 179 作業室の作業環境測定を計画通りに実施しました。

また、放射線総合管理システム（登録者数 : 3,444 名、抹消者を含んだ登録者数：27,091 名）の管理運用を行いました。放射性同位元素等の規制に関する法律で規定されている放射線教育訓練について、今年度は授業支援システム（CLE）を活用し、配信によって計 15 回（1,921 名）を開催しました。

2. 放射線教育に関する業務

安全教育事業の一つとして、放射線取扱主任者試験の受験を奨励し、対策講座について CLE を利用してオンラインで 7 回実施し、受験申込書を配付しました。対策講座を受講した者は 32 名でした。豊中消防局への放射III

線教育の一環として、消防局職員 15 名に豊中分館の見学を実施しました。

Achievements

3. RI センター施設の共同利用

共同利用については、利用状況に応じて実験室等の専有状況を随時見直し、効率的に共同利用に供しています。今年度の共同利用申請件数は 53 件、利用者数は 616 名でした。

IRS ANNUAL REPORT

2022

58

NAME INDEXNameC CHIU, I-Huan
D DU, JuanF FUKASE, Koichi

Name

Page

O OGAWA, Izumi

28

26

OHNO, Mizuki

195, 6, 16, 23, 27

OKADA, Michio

7, 21

FUKUDA, Mitsuhiro

16

OOE, Kazuhiro

6, 11, 16, 22, 23, 27

FURUNO, Tatsuya

25

OTA, Shinsuke

25

G GIESEL, Frederik L.
H HABA, Hiromitsu

6, 23, 27
6, 16, 22, 23

R RITTIRONG, Anawat

28

ROKUJO, Hiroki

25

S SAKAKI, Hironao

25

24

SAWAMURA, Kei

17

25

17

I INOUE, Azusa

SHIGEKAWA, Yudai

25

SHIMOYAMA, Atsushi

6, 16

ISHIDA, Yohta

18

SHINOHARA, Atsushi

6, 17, 23

ISHIKAWA-FUJIWARA, Tomoko 7, 15

SHIRAKAMI, Yoshifumi

5, 6, 16, 22, 23, 27

IWASAKI, Ryota

25

SUDO, Takashi

25

6, 16

SUZUKI, Tomokazu

9, 24

HATAZAWA, Jun

6, 22, 23

HIGAKI, Shogo
HONDA, Yuya

K KABAYAMA, Kazuya

T TAKAHASHI, Masaomi

KADONAGA, Yuichiro

6, 23, 27

KANAI, Yoshikatsu

16

TAMII, Atsushi

25

KANEDA-NAKASHIMA, Kazuko

6, 16, 23, 27, 29

TERAMOTO, Takahiro

5, 23, 26

KASAMATSU, Yoshitaka

17

TODO, Takeshi

15

KAWABATA, Takahiro

11, 25

TOKI, Hiroshi

6, 19

KOBAYASHI, Nobuyuki

25

TOKITA, Shigeki

28

KOBAYASHI, Takayoshi

26

TOMIYAMA, Noriyuki

3, 6, 27

KOKI, Ryoichi

9

TOYOSHIMA, Atsushi

5, 6, 16, 23, 27

KON, Akira

25

TSUJI, Seiya

25

KON, Yukiyoshi

9, 23

KONDO, Kotaro

25

L LIU, Chang

U UMEHARA, Saori
W WATABE, Tadashi

25

WIELAND, Oliver

LIU, Jun

26

M MANABE, Yoshiyuki

Y YAJIMA, Tatsuo

16

YASUDA, Yuki

17

MASUDA, Ryoutarou

17

YIN, Xiaojie

23

MIYAMOTO, Kenshin

25

YONEKURA, Yoshiharu

5, 6

MIYAMOTO, Yuki

17

YOSHIDA, Sei

28

MURATA, Isao

11

YOSHIMURA, Koji

17

11, 12, 18, 29

YOSHIMURA, Takashi

6, 9, 11, 12, 16, 18, 29

N NAGATA, Kojiro

59

Page

20

NAKAJIMA, Hiroo

6, 7, 19

NAKANO, Takashi

6, 16

NAKAZAWA, Kazuma

25

NAMBU, Akihiro

22

NIIKURA, Megumi

25

NIINA, Rei

25

NINOMIYA, Kazuhiro

11, 20NISHIUCHI, Mamiko

25

NISHIZAWA, Hayato

29

NOMACHI, Masaharu

7

IRS ANNUAL REPORT

2022

24

28
6, 16, 22, 23, 27
25
12, 18IRS ANNUAL REPORT

2022

Volume 4

IRS ANNUAL REPORT

2022

60

Institute for Radiation Sciences
Toyonaka Oﬃce

1-1, Machikaneyama, Toyonaka, Osaka 560-0043
Tel : 06-6850-8271
Suita Oﬃce

2-4, Yamadaoka, Suita, Osaka 565-0871
Tel : 06-6879-8827

https://www.irs.osaka-u.ac.jp/